

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

217186Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA #:	217,186
Supplement #:	0001
Drug Name:	IPX203
Indication(s):	A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-release Carbidopa Levodopa in Parkinson's Disease Patients with Motor Fluctuations
Applicant:	Impax Laboratories, LLC
Date(s):	Submission date: 08/31/2022, PDUFA date: 06/30/2023
Review Priority:	Standard
Biometrics Division:	Division of Biometrics I
Statistical Reviewer:	Minjeong Park, Ph.D., Primary Reviewer
Concurring Reviewers:	John Lawrence, Ph.D., Secondary Reviewer H.M. James Hung, Ph.D., Division Director
Medical Division:	Division of Neurology I
Clinical Team:	Elizabeth Haberkfeld, M.D.
Project Manager:	Stacy Metz, PharmD.
Keywords: LOCF, MMRM, Multiple Imputation, Wilcoxon Rank Sum Test	

Table of Contents

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION	6
2.1	OVERVIEW	6
2.2	DATA SOURCES	6
3	STATISTICAL EVALUATION	7
3.1	DATA AND ANALYSIS QUALITY.....	7
3.2	EVALUATION OF EFFICACY IN IPX203-B16-02.....	7
3.2.1	<i>Study Design and Endpoints</i>	<i>7</i>
3.2.2	<i>Statistical Methodologies.....</i>	<i>8</i>
3.2.3	<i>Patient Disposition, Demographic/Baseline Disease Characteristics, Infusion rates</i>	<i>12</i>
3.2.4	<i>Efficacy Results.....</i>	<i>17</i>
3.2.4.1	Primary Endpoint: “Good on” Time.....	17
3.2.4.1.1	Sensitivity Analyses of Primary Endpoint	19
3.2.4.1.2	Supportive Analyses of Primary Endpoint.....	19
3.2.4.2	Key Secondary Endpoints	20
3.2.4.2.1	“Off” Time	20
3.2.4.2.2	PGI-C Scores.....	22
3.2.4.2.3	MDS-UPDRS Part III	23
3.3	EVALUATION OF SAFETY	24
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS.....	24
5	SUMMARY AND CONCLUSIONS	32
5.1	STATISTICAL ISSUES	32
5.2	COLLECTIVE EVIDENCE	32
5.3	CONCLUSIONS AND RECOMMENDATIONS.....	32
6	APPENDIX I : MODEL DIAGNOSTICS.....	33
7	APPENDIX II : ADDITIONAL EFFICACY ANALYSES BY REQUESTS	53

LIST OF TABLES

Table 1. Summary of study included in analysis	6
Table 2. Subject Disposition in the DBP	13
Table 3. Demographic characteristics in DBP (mITT Analysis Set).....	14
Table 4. Baseline Characteristics (mITT Analysis Set).....	15
Table 5. Primary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set).....	17
Table 6. Sensitivity Analyses of Primary Efficacy Endpoint (“Good on” Time) in mITT Analysis Set	19
Table 7. Supportive Analyses of Primary Efficacy Endpoint (“Good on” Time)	19
Table 8. Key Secondary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set).....	20
Table 9. Sensitivity Analyses of Key Secondary Efficacy Endpoint (“Off” Time) in mITT Analysis Set.....	22
Table 10. Supportive Analyses of Key Secondary Efficacy Endpoint (“Off” Time).....	22
Table 11. Key Secondary Efficacy Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)..	23
Table 12. Key Secondary Efficacy Endpoint: Change from Baseline to Visit7/ET in MDS-UPDRS Part III during DBP by Randomized Treatment Group (ITT Analysis Set).....	23
Table 13. Subgroup Analyses of Primary Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set).....	25
Table 14. Subgroup Analyses of Key Secondary Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set).....	27
Table 15. Subgroup Analyses of Key Secondary Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)	29

LIST OF FIGURES

Figure 1. Study Schema	7
Figure 2. Subject Disposition Flowchart	13
Figure 3. Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)	18
Figure 4. Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)	21
Figure 5. Forest Plot of Subgroup Analysis for Primary Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)	26
Figure 6. Forest Plot of Subgroup Analysis for Key Secondary Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)	28
Figure 7. Forest Plot of Subgroup Analysis for Key Secondary Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)	30

1 EXECUTIVE SUMMARY

Impax Laboratories, LLC, submitted one phase 3 study (IPX203-B16-02) to support the claim of the efficacy and safety of IPX203 in comparison to immediate-release (IR) carbidopa-levodopa (CD-LD) in the treatment of CD-LD experienced subjects with Parkinson's disease who have motor fluctuations. In the primary analysis on the change in "Good on" time from baseline (end of 4-week open-label dose conversion period for conversion from IR CD-LD to IPX203) to Visit 7/early termination (ET), the least square (LS) mean difference between IPX203 versus IR CD-LD was statistically significant (0.5293, 95% CI: [0.0859, 0.9727], p-value =0.0194), indicating less decrease of "Good on" time from baseline to Visit 7/ET in the IPX203 group compared to the IR CD-LD group. The first key secondary analysis showed a significantly less increase of "Off" time from baseline to Visit 7/ET for the IPX203 group compared to the IR CD-LD group (p-value=0.0252). The second key secondary analysis also showed a statistically significant difference in proportions of subjects who answered "Much improved" or "Very much improved" in patient global impression of change (PGI-C) in a comparison between the IPX203 group to the IR CD-LD group (p-value = 0.0015). Findings from efficacy evaluation in the phase 3 confirmatory study (IPX203-B16-02) support a greater treatment effect of IPX203 compared to the IR CD-LD in "Good on" time, "Off" time and PGI-C.

2 INTRODUCTION

2.1 Overview

This application contains one phase 3 confirmatory study which was designed as a randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study, consisting of a 3-week, open-label immediate-release (IR) carbidopa-levodopa (CD-LD) dose adjustment period, a 4-week, open-label period for conversion to IPX203 followed by a 13-week double-blind treatment period, to evaluate the efficacy and safety of IPX203 in comparison to IR CD-LD in the treatment of CD-LD experienced subjects with Parkinson's disease (PD) who have motor fluctuations.

Table 1. Summary of study included in analysis

Protocol No.	Phase and Design	Treatment Period	# of Subjects randomized and received any blinded study drug per Arm	Study Population
IPX203-B16-02	R, DB, DD, AC, PG, MC	IR CD-LD Dose Adjustment: 3 weeks Dose Conversion to IPX203: 4 weeks Double-blind Maintenance: 13 weeks	IPX203: 256 IR CD-LD: 250	Male or female subjects diagnosed at age ≥ 40 years with PD

Abbreviations: R=randomized, DB=double-blind, DD=double-dummy, AC=active-controlled, PG=parallel-group, MC=multicenter, IR=immediate-release, CD-LD=carbidopa-levodopa, PD=Parkinson's disease.

2.2 Data Sources

All documents reviewed for this supplement submission are in electronic form.

The electronic location of the submission is <\\CDSESUB1\evsprod\NDA217186\0001>.

SDTM located at: <\\CDSESUB1\evsprod\NDA217186\0001\m5\datasets\ipx203-b16-02\tabulations\sdm>.

ADaM located at: <\\CDSESUB1\evsprod\NDA217186\0001\m5\datasets\ipx203-b16-02\analysis\adam\datasets>.

3 STATISTICAL EVALUATION

3.1 Data and Analysis Quality


The sponsor submitted all necessary analysis datasets and SAS programs. This reviewer found the datasets acceptable. With these, this reviewer verified the analysis datasets and the primary results from the clinical study report.

3.2 Evaluation of Efficacy in IPX203-B16-02

3.2.1 Study Design and Endpoints

Study IPX203-B16-02 was a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group, prospective study with a duration of 24 weeks, consisting of an up to 4-week screening period, a 3-week open-label IR CD-LD dose adjustment period, a 4-week open-label period for conversion to IPX203, and a 13-week double-blind, double-dummy treatment period (Figure 1). During the IR CD-LD dose adjustment period, the initial dosing regimen of IR CD-LD was to be the same as the subject's stable pre-study regimen unless the subject was taking a single daily bedtime dose of controlled-release (CR) CD-LD. In such a case, the CR CD-LD dose was discontinued and substituted with a 1:1 milligram-equivalent dose of IR CD-LD. Following completion of the IR CD-LD dose adjustment period, subjects began a 4-week open-label dose conversion period for conversion from IR CD-LD to IPX203. The initial dosing regimen of IPX203 was based on the most frequent dose according to the prespecified conversion instructions. Subjects who successfully completed the IPX203 dose conversion period were randomized in a 1:1 ratio, stratified by center, at Visit 4 to one of two parallel treatment arms of IPX203 (with matching IR CD-LD placebo) or IR CD-LD (with matching IPX203 placebo), and underwent 13-weeks of double-blind, double-dummy maintenance therapy with the stable dosing regimen established at the end of Week 3 for IR CD-LD and at the end of Week 7 for IPX203.

Figure 1. Study Schema



Abbreviations: ET=early termination, IR CD-LD=immediate-release carbidopa-levodopa, PD=Parkinson's disease
Source: Sponsor; Protocol IPX203-B16-02

The primary efficacy endpoint was the mean change from baseline in “Good on” time in hours per day, averaged over the PD Diary days, at the end of double-blind treatment period (Visit 7 or early termination (ET)). “Good on” time was derived from the 3-day PD diaries and was defined as the sum of “On time without dyskinesia” and “On time with non-troublesome dyskinesia”. For the PD diary, subjects were to record “asleep,” “Off,” and “On” without or with (non-troublesome or troublesome) dyskinesias during waking hours every 30 minutes over a 24-hour day. A valid diary was defined as a diary with missing less than 2 hours (4 half periods) of the 24-hours.

The key secondary endpoints were as follows: 1) change from baseline in “Off” time in hours per day, averaged over the PD diary days at the end of double-blind treatment period (Visit 7 or ET), 2) proportion of subjects with either “much improved” or “very much improved” in Patient Global Impression of Change (PGI-C) scores at the end of double-blind treatment period (Visit 7 or ET), 3) change from baseline in the MDS-UPDRS Part III at the end of double-blind treatment period (Visit 7 or ET), 4) change from baseline in the sum of MDS-UPDRS Part II and III at the end of double-blind treatment period (Visit 7 or ET).

For the PGI-C, the patient will compare his/her condition from the start of the study on a 7-point scale ranging from “Very much worse” (1) to “Very much improved” (7) at the time of the assessment. The MDS-UPDRS part II includes Motor Aspects of Experiences of Daily Living (M-EDL) which is a self-administered questionnaire but can be reviewed by the investigator to ensure completeness and clarity. The MDS-UPDRS part III includes Motor Examination which assesses the motor signs of PD and has instructions for the rater to give to or to demonstrate to the patient.

3.2.2 Statistical Methodologies

Sponsor’s Methods

Power and sample size determination

Assuming a difference of 1 hour between IPX203 and IR CD-LD in “Good on” time and a standard deviation of the treatment differences to be 3.0 hours, a sample size of 210 subjects per arm was needed to ensure at least 90% power at a 0.05 significance level.

Assuming approximately an 18% pre-randomization drop-out, approximately 510 subjects would need to be enrolled to randomize 420 subjects.

Analysis sets

The intent-to-treat (ITT) analysis set included all subjects who were randomized and treated with any study drug and have a baseline and at least one post-baseline efficacy assessment.

The modified intent-to-treat (mITT) analysis set included all subjects who were randomized and treated and had a valid baseline PD diary and at least one valid post-randomization PD diary.

This analysis set will be used for the primary analysis and key secondary analyses.

Efficacy analyses

[Primary efficacy analysis]

The primary efficacy endpoint was analyzed using a mixed model for repeated measures (MMRM). The model included baseline (Visit 4) “Good on” time as a covariate, treatment

(IPX203 or IR CD-LD) and visit (5, 6, or 7/early termination (ET)) as fixed effects, pooled center as a random effect and a treatment-by-visit interaction. The model employed an unstructured within subject covariance matrix and a restricted maximum likelihood (ReML) estimation method. The degree-of-freedom of the denominator was estimated using the Kenward-Roger method. The primary analysis set was the mITT. If the model failed to converge with the unstructured covariance matrix, a simpler covariance matrix was to be employed in the order of 1) heterogeneous Toeplitz, 2) heterogeneous autoregressive of order 1, 3) heterogeneous compound symmetry, 4) Toeplitz, 5) autoregressive of order 1, 6) compound symmetry (CS). Missing visit data were handled via the MMRM model.

Imputation method for PD diary data

A PD Diary is valid if at least 1 day of diary data is available using the rules defined below. Imputation of missing data for subject PD diaries will be required if the PD diary is not completed for a full day (from 6:00 am to 6:00 am the next day). In this case, the method of imputation depends on the amount and pattern of missing data:

- For subjects with more than 1 day of diary data, the following rules will apply:
 - If more than 4 half-hour time intervals are missing, then that particular day will not be included in the analysis. The missing data will be handled in the MMRM model.
 - If a half-hour time interval is missing and the observations on either side of the time interval are not missing, then the missing time interval will be imputed by assigning a value of the previous measurement for the first 15 minutes and the value of the next measurement for the second 15 minutes.
 - If 2, 3 or 4 half-hour time intervals are missing, and these time intervals are available from other days of the visit, then the following rules will be applied:
 - For missing values on Day -3, data from Day -2 will be used for imputation for the same time intervals. If Day -2 data is also incomplete or not available, then Day -1 data will be used.
 - For missing values on Day -2, data from Day -1 will be used for imputation if available; otherwise, Day -3 data will be used.
 - For missing values on Day -1, data from Day -2 will be used for imputation if available; otherwise, Day -3 data will be used for imputation.
 - If data at the same time period are missing across all days, then the approach will be to split the individual missing half-hour intervals into 2 periods, with the first half-interval being imputed with data from the immediate previous non-missing time period and the second half-interval being imputed with the next non-missing time interval. If the missing period starts with the very first or ends with the very last interval of the diary, then the entire missing period will be imputed with the data from the immediate adjacent non-missing interval.
- For subjects with only 1 day of diary data (instead of 3 day), the following rules will apply:
 - If more than 4 half-hour time intervals are missing, then that particular day will not be included in the analysis. The missing data will be handled in the MMRM model.
 - If a one-half hour time interval is missing and the observations on either side of the time interval are not missing, then the missing time interval will be imputed by assigning a value of the previous measurement for the first 15 minutes and the value of the next measurement for the second 15 minutes.

- o If 2, 3, or 4 consecutive half-hour intervals are missing, then the approach will be to split the individual missing half-hour intervals into 2 periods, with the first half-interval being imputed with data from the immediate previous non-missing time period and the second half-interval being imputed with the next non-missing time interval. If the missing period starts with the very first or end with the very last interval of the diary, then the entire missing period will be imputed with the data from the immediate adjacent non-missing interval.

[Key secondary efficacy analyses]

1. **Change from baseline in “Off” time at the end of double-blind treatment period** (Visit 7/ET) was analyzed similar to the primary endpoint.
2. **Proportion of subjects with either “much improved” or “very much improved” in Patient Global Impression of Change (PGI-C) scores** at the end of double-blind treatment period (Visit 7/ET) was analyzed using Cochran-Mantel-Haenszel (CMH) test stratified by the pooled center to compare the proportion of subjects with either “much improved” or “very much improved” response at the end of the double-blind therapy between the two treatment groups.
3. **Change from baseline in the MDS-UPDRS Part III total score as the sum of the answer for all questions** at the end of double-blind treatment period (Visit 7/ET) was analyzed in the same manner as the primary endpoint.
4. **Change from baseline in the sum of MDS-UPDRS Part II and III as the sum of all answers** at the end of double-blind treatment period (Visit 7/ET) was analyzed in the same manner as MDS-UPDRS Part III.

Missing data for MDS-UPDRS

If the MDS-UPDRS was missing for the particular visit, the missing data was to be handled via the MMRM model.

If component question were missing for a particular part of the MDS-UPDRS questionnaire, the missing items were assigned the average value for other items in that part as follows:

- For Part I (13 questions): up to 1 missing question was to be imputed using the average value of the remaining 12 questions.
- For Part II (13 questions): up to 2 missing questions were to be imputed using the average value of the remaining 11 questions.
- For Part III (33 questions): up to 7 missing questions were to be imputed using the average value of the remaining 26 questions.
- For Part IV (6 questions): no imputation was to be done.

If more component questions were missing than above for a particular part of the MDS-UPDRS questionnaire, the entire questionnaire and the affected part were not to be included in the analysis for that particular assessment.

Multiplicity adjustment

The primary endpoint and 4 key/important secondary endpoints were tested in a sequential hierarchical order as follows:

1. The primary endpoint, the mean change from baseline in “Good on” time (hours per day), was tested first at a 0.05 level of significance.
2. If statistical significance is demonstrated, then the first key secondary endpoint, the mean change from baseline in “Off” time (hours per day), was tested next at a 0.05 level of significance.
3. If statistical significance is demonstrated, then the second key secondary endpoint, the proportion of subjects with either “much improved” or “very much improved” on the PGI-C, was tested next at a 0.05 level of significance.
4. If statistical significance is demonstrated, then the third key secondary endpoint, the mean change from baseline in the MDS-UPDRS Part III, was tested at a 0.05 level of significance.
5. If statistical significance is demonstrated, then the fourth key secondary endpoint, the mean change from baseline in the sum of the MDS-UPDRS Parts II and III combined was tested next at a 0.05 level of significance.
6. If statistical significance is demonstrated, then the important secondary endpoint, being “on” upon awakening was tested next at a 0.05 level of significance.

Sensitivity Analyses

1. Assessing Assumptions of the MMRM: After the normality and homoscedasticity assumption test, the following non-parametric analyses were performed if either of the tests was significant.
 - a. Nonparametric Wilcoxon Rank Sum test after imputing missing data using last observation carried forward (LOCF) method.
 - b. Multiple imputation rank-based analysis: missing at Visit 7 were imputed multiple times to create 50 complete datasets using the multiple imputation procedure.
2. Complete case analysis: the primary endpoint was analyzed using ANCOVA model on the completers analysis set.
3. Single LOCF/BLOCF imputation: the primary endpoint was analyzed using ANCOVA model after imputing missing data by LOCF or baseline observation carried forward (BLOCF) methods.
4. Site as fixed effect: the MMRM model was used similar to the primary analysis, except pooled site was used as a fixed effect rather than random.
5. Region effect: the MMRM model was used similar to the primary analysis, except geographic region (North America or Europe) was used as a fixed effect instead of pooled sites as random effect.
6. Per-protocol analysis: the analysis of primary and key secondary endpoints were repeated on the per-protocol analysis set.
7. Pattern-mixture model: if an overall dropout rate post-randomization is >15%, pattern-mixture models (PMM) was employed to assess the robustness of the results under the missing not at random (MNAR) assumption. Because the overall dropout rate post-randomization did not exceed 15%, this sensitivity analysis was not conducted.

Subgroup Analysis


- Age: < 65, ≥ 65 years old at study entry
- Sex: Males, Females
- Race: Caucasians, non-Caucasians
- Region: North America or Europe
- Ethnicity: Hispanic, Non-Hispanic or Unknown
- Concomitant medications: the following non-exclusive subgroups will be defined for subjects taking concomitant medications of the following categories:
 - o Amantadine
 - o selective MAOB inhibitors
 - o anticholinergic PD medications
 - o dopamine agonists
 - o others
- Weight: <75 kg or ≥75 kg
- Body mass index (BMI): <25 kg/m² or ≥25 kg/m²
- PD duration at screening: <8 years or ≥8 years
- Age of PD onset: <65 years or ≥65 years
- “Good On” time at study entry: average <9h or ≥9h per day
- “Off” time at study entry: average <6h or ≥6h per day

3.2.3 Patient Disposition, Demographic/Baseline Disease Characteristics, Infusion rates

A total of 770 subjects were screened, 630 subjects were enrolled in the study. Among 630 enrolled subjects entered the IR CD-LD dose adjustment period, 589 subjects completed and entered the IPX203 conversion period. A total of 506 subjects were completed IPX203 conversion period and randomized to either IPX203 (n=256) or IR CD-LD (n=250) (Figure 2). Of these, 57 subjects discontinued early from the double-blind maintenance period; 34 subjects (13.3%) from IPX203 group and 23 (9.2%) subjects from the IR CD-LD group due to following primary reasons; 1) adverse event (AE) – 14 (41.2%) in IPX203 and 3 (13.0%) in IR CD-LD, 2) withdrawal by subjects – 10 (29.4%) in IPX203 and 11 (47.8%) in IR CD-LD, 3) lack of efficacy – 5 (14.7%) in IPX203 and 8 (34.8%) in IR CD-LD, 4) protocol deviation – 3 (8.8%) in IPX203 and 1 (4.3%) in IR CD-LD, 5) non-compliance with study drug – 1 (2.9%) in IPX203, and 6) other – 1 (2.9%) in IPX203 (Table 2).

All 506 subjects who were randomized to the double-blind period were included in the safety analysis set and the ITT analysis set, 495 (97.8%) subjects were included in the mITT analysis set, 446 (88.1%) subjects in the completers analysis set, and 313 (61.9%) subjects in the PP Analysis Set (Table 2).

Figure 2. Subject Disposition Flowchart



Abbreviations: IR CD-LD=immediate-release carbidopa-levodopa, mITT=modified intent-to-treat, PP=per-protocol.
Source: Sponsor; Clinical Study Report page 87

Table 2. Subject Disposition in the DBP

Disposition	Number (%) of Subjects Randomized		
	IPX203 (N=256)	IR CD-LD (N=250)	Total (N=506)
Completed the double-blind period	222 (86.7)	227 (90.8)	449 (88.7)
Early discontinuation from the double-blind period	34	23	57
Primary reason for discontinuation			
Adverse event	14 (41.2)	3 (13.0)	17 (29.8)
Lost to follow-up	0	0	0
Lack of efficacy	5 (14.7)	8 (34.8)	13 (22.8)
Non-compliance with study drug	1 (2.9)	0	1 (1.8)
Protocol deviation	3 (8.8)	1 (4.3)	4 (7.0)
Withdrawal by subject	10 (29.4)	11 (47.8)	21 (36.8)
Other	1 (2.9)	0	1 (1.8)
Safety analysis set	256 (100)	250 (100)	506 (100)
ITT analysis set	256 (100)	250 (100)	506 (100)
mITT analysis set	249 (97.3)	246 (98.4)	495 (97.8)
Per-protocol analysis set	155 (60.5)	158 (63.2)	313 (61.9)

Disposition	Number (%) of Subjects Randomized		
	IPX203 (N=256)	IR CD-LD (N=250)	Total (N=506)
Completers analysis set	220 (85.9)	226 (90.4)	446 (88.1)

Abbreviations: DBP=double-blind treatment period, IR CD-LD=immediate-release carbidopa-levodopa, ITT=intent-to-treat, mITT=modified intent-to-treat

Safety analysis set includes all subjects who were randomized and received at least one dose of study treatment.

mITT analysis set includes all subjects who were randomized and treated and had a valid baseline PD diary and at least one valid post-randomization PD diary.

Source: Statistical Reviewer Analysis; *adsl.xpt*, *ds.xpt*

The demographic characteristics by the randomized treatment group and dose category in the mITT population are shown in Table 3. Subjects were between ages of 40 and 89 years, the mean ages in both groups were approximately 66 years old. The proportion of male subjects were higher in both groups; 61.0% in IPX203 and 70.7% in IR CD-LD. A majority of subjects were White.

Table 3. Demographic characteristics in DBP (mITT Analysis Set)

Characteristic	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Age, years			
n	249	246	495
Mean (SD)	66.1 (9.00)	66.6 (8.83)	66.3 (8.91)
Median	66.0	68.0	67.0
IQR	59.0, 72.0	61.0, 73.0	60.0, 72.0
Min, Max	44.0, 88.0	40.0, 89.0	40.0, 89.0
Age group, n (%)			
< 65 years	97 (39.0)	90 (36.6)	187 (37.8)
≥ 65 years	152 (61.0)	156 (63.4)	308 (62.2)
Sex, n (%)			
Male	152 (61.0)	174 (70.7)	326 (65.9)
Female	97 (39.0)	72 (29.3)	169 (34.1)
Race, n (%)			
White	237 (95.2)	239 (97.2)	476 (96.2)
Black or African American	2 (<1)	3 (1.2)	5 (1.0)
Asian	5 (2.0)	2 (<1)	7 (1.4)
American Indian or Alaska Native	3 (1.2)	0	3 (<1)
Unknown or not reported	2 (<1)	2 (<1)	4 (<1)
Ethnicity, n (%)			
Hispanic or Latino	32 (12.9)	31 (12.6)	63 (12.7)
Not Hispanic or Latino	216 (86.7)	211 (85.8)	427 (86.3)
Not reported	1 (<1)	4 (1.6)	5 (1.0)
Height, years			
n	249	246	495
Mean (SD)	168.9 (10.16)	171.7 (9.95)	170.3 (10.14)
Median	170.0	172.7	171.0
IQR	162.0, 176.0	164.0, 180.0	162.6, 177.8
Min, Max	124.5, 195.4	145.0, 193.0	124.5, 195.4

Characteristic	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Weight, years			
n	248	246	494
Mean (SD)	78.6 (17.69)	80.9 (16.87)	79.8 (17.31)
Median	77.4	78.6	78.1
IQR	65.7, 89.2	70.0, 90.0	68.2, 89.8
Min, Max	41.8, 139.2	45.0, 140.1	41.8, 140.1
BMI, years			
n	248	246	494
Mean (SD)	27.4 (5.06)	27.3 (4.66)	27.4 (4.86)
Median	27.0	26.8	27.0
IQR	23.9, 30.4	24.2, 30.2	24.2, 30.3
Min, Max	16.3, 52.6	17.6, 45.1	16.3, 52.6

Abbreviations: DBP=double-blind treatment period, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, IQR=interquartile range, SD=standard deviation, Min=minimum, Max=maximum, BMI=body mass index.

Source: Statistical Reviewer Analysis; adsl.xpt

Table 4 displays the baseline characteristics including values for each part of MDS-UPDRS in the “ON” and “OFF” state, Hoehn and Yahr stage in the “ON” state, and MoCA scores. These baseline characteristics were comparable in both groups. The mean (standard deviation (SD)) age of onset of PD was 57.7 (9.08) in the IPX203 and 58.4 (9.60) in the IR CD-LD group.

Table 4. Baseline Characteristics (mITT Analysis Set)

Characteristic	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Screening MDS-UPDRS Part I Total Score, “ON” State			
n	248	244	492
Mean (SD)	10.50 (5.60)	9.88 (5.24)	10.19 (5.43)
Median	10.0	9.50	10.0
IQR	6.50, 13.50	6.0, 13.0	6.0, 13.0
Min, Max	0.0, 27.0	0.0, 24.0	0.0, 27.0
Screening MDS-UPDRS Part II Total Score, “ON” State			
n	248	244	492
Mean (SD)	13.06 (7.37)	12.50 (7.22)	12.78 (7.29)
Median	12.0	12.0	12.0
IQR	8.0, 18.0	7.0, 17.0	8.0, 17.50
Min, Max	0.0, 38.0	0.0, 43.0	0.0, 43.0
Screening MDS-UPDRS Part III Total Score, “ON” State			
n	249	246	495
Mean (SD)	24.83 (16.09)	24.88(15.61)	24.86 (15.84)
Median	21.0	22.0	22.0
IQR	14.0, 33.0	13.0, 32.0	13.0, 32.0
Min, Max	3.0, 96.0	3.0, 97.0	3.0, 97.0

Characteristic	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Screening MDS-UPDRS Part IV Total Score, “ON” State			
n	248	244	492
Mean (SD)	7.13 (2.83)	7.25 (2.63)	7.19 (2.73)
Median	7.0	7.0	7.0
IQR	5.0, 9.0	5.0, 9.0	5.0, 9.0
Min, Max	0.0, 16.0	2.0, 16.0	0.0, 16.0
Screening MDS-UPDRS Part I Total Score, “OFF” State			
n	249	246	495
Mean (SD)	11.06 (5.80)	10.89 (5.39)	10.98 (5.59)
Median	11.0	10.0	10.0
IQR	7.0, 15.0	7.0, 14.0	7.0, 14.0
Min, Max	0.0, 28.0	0.0, 26.0	0.0, 28.0
Screening MDS-UPDRS Part II Total Score, “OFF” State			
n	249	246	495
Mean (SD)	15.14 (7.66)	15.30 (7.60)	15.22 (7.62)
Median	14.0	14.0	14.0
IQR	9.0, 20.0	10.0, 20.0	10.0, 20.0
Min, Max	1.0, 38.0	1.0, 43.0	1.0, 43.0
Screening MDS-UPDRS Part III Total Score, “OFF” State			
n	249	246	495
Mean (SD)	45.57 (13.98)	45.64 (14.17)	45.60 (14.06)
Median	44.0	44.0	44.0
IQR	36.0, 54.0	36.0, 54.0	36.0, 54.0
Min, Max	20.0, 99.0	21.0, 98.0	20.0, 99.0
Screening MDS-UPDRS Part IV Total Score, “OFF” State			
n	249	246	495
Mean (SD)	7.20 (2.69)	7.32 (2.65)	7.26 (2.67)
Median	7.0	7.0	7.0
IQR	5.0, 9.0	5.0, 9.0	5.0, 9.0
Min, Max	3.0, 16.0	2.0, 16.0	2.0, 16.0
Hoehn and Yahr Stage, “ON” State, n (%)			
0	0	0	0
1	26 (10.4)	20 (8.1)	46 (9.3)
2	168 (67.5)	172 (69.9)	340 (68.7)
3	49 (19.7)	47 (19.1)	96 (19.4)
4	6 (2.4)	7 (2.8)	13 (2.6)
5	0	0	0
Screening MoCA Score, n (%)			
< 24	0	0	0
24 - < 26	54 (21.7)	53 (21.5)	107 (21.6)
26 - < 28	69 (27.7)	82 (33.3)	151 (30.5)
28 - < 30	102 (41.0)	89 (36.2)	191 (38.6)
30	24 (9.6)	22 (8.9)	46 (9.3)

Characteristic	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Age of Onset of PD, years			
n	249	246	495
Mean (SD)	57.7 (9.08)	58.4 (9.60)	58.1 (9.34)
Median	58.0	58.5	58.0
IQR	51.0, 64.0	51.0, 65.0	51.0, 65.0
Min, Max	40.0, 83.0	34.0, 83.0	34.0, 83.0

Abbreviations: DBP=double-blind treatment period, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, n=number, IQR=interquartile range, SD=standard deviation, Min=minimum, Max=maximum, BMI=body mass index.

Source: Statistical Reviewer Analysis; adsl.xpt

3.2.4 Efficacy Results

3.2.4.1 Primary Endpoint: “Good on” Time

Table 5 summarized the descriptive statistics of “Good on” time at baseline (end of 4-week open-label dose conversion period for conversion from IR CD-LD to IPX203), Visit 7 (Week 13), the change from baseline to Visit 7, and the least squares (LS) mean change and its standard error (SE) from baseline to Visit 7 by the treatment group, the LS mean difference between two treatment groups at Visit 7 and its 95% confidence interval (CI). The LS mean change (SE) in “Good on” time from baseline to Visit 7 was -0.385 (2.706) hours in IPX203 and -0.968 (3.081) hours in IR CD-LD, indicating less decrease of “Good on” time in the IPX203 group by 0.5293 hours (95% CI = (0.0859, 0.9727), $p = 0.0194$), compared with the IR CD-LD group.

Table 5. Primary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)

Statistics (hour)	Randomized Treatment Group		
	IPX203 (N=249)	IR CD-LD (N=246)	Total (N=495)
Baseline visit			
N	249	246	495
Mean (SD)	11.671 (2.943)	11.724 (2.759)	11.697 (2.850)
Median (Q1, Q3)	12.0 (10.17, 13.50)	11.67 (9.83, 13.67)	11.83 (10.08, 13.67)
Min., Max.	0.50, 18.83	1.83, 18.0	0.50, 18.83
Visit 7 (Week 13)			
N	235	241	476
Mean (SD)	11.349 (3.065)	10.773 (2.775)	11.057 (2.933)
Median (Q1, Q3)	11.50 (9.33, 13.50)	10.83 (9.0, 12.67)	11.17 (9.17, 13.0)
Min., Max.	0, 17.67	1.50, 17.0	0.0, 17.67
Change at Visit 7 (Week 13) from baseline			
N	235	241	476
Mean (SD)	-0.385 (2.706)	-0.968 (3.081)	-0.680 (2.914)
Median (Q1, Q3)	-0.33 (-1.83, 1.17)	-1.0 (-2.67, 0.83)	-0.71 (-2.17, 1.0)
Min., Max.	-9.67, 8.50	-9.33, 8.0	-9.67, 8.50

Statistics (hour)	Randomized Treatment Group		Total (N=495)
	IPX203 (N=249)	IR CD-LD (N=246)	
LS Mean change (SE) at Week 12 from baseline	-0.5012 (0.1834)	-1.0305 (0.1828)	
LS Mean difference (95% CI) (IPX203 vs. IR CD-LD)	0.5293 (0.0859, 0.9727)		
p-value	0.0194		


Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, Max=maximum, Min=minimum, Q1=quarter 1, Q3=quarter 3, LS=least squares, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddp.xpt*, *adsl.xpt*

Figure 3 shows the LS mean change in “Good on” time from baseline to each follow-up visit and its 95% CI during DBP by the treatment group; red for IPX203-treated and blue for IR CD-LD-treated subjects. The figure illustrates that “Good on” time decreased less in IPX203-treated subjects compared with the IR CD-LD-treated subjects.

Figure 3. Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)



Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, No.=number.

The LS means, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddp.xpt*, *adsl.xpt*

3.2.4.1.1 Sensitivity Analyses of Primary Endpoint

The results of the normality assumption check are presented in Appendix I. Due to the failure of the normality test, non-parametric analyses were conducted as a sensitivity analysis. Using the mITT analysis set, the following sensitivity analyses were included; 1) MMRM after imputation with LOCF, 2) ANCOVA after imputation with LOCF using changes at Visit 7, 3) MMRM after imputation with BLOCF, 4) ANCOVA after imputation with BLOCF using changes at Visit 7, 5) Wilcoxon rank sum test after imputation with LOCF using changes at Visit 7, 6) multiple imputation rank-based analysis, 7) pooled site used as a fixed effect rather than random, 8) geographic region used as a fixed effect instead of pooled site as a random effect. Sensitivity analyses of “Good on” time for the IPX203 compared to the placebo group demonstrated that the impact from missing data did not change the conclusion for the primary analysis (Table 6).

Table 6. Sensitivity Analyses of Primary Efficacy Endpoint (“Good on” Time) in mITT Analysis Set

Sensitivity Analysis Type	IPX203 vs. IR CD-LD	
	LS Mean Difference (95% CI)	p-value
LOCF (MMRM)	0.4885 (0.0473, 0.9297)	0.0301
LOCF (ANCOVA)	0.5009 (0.0640, 0.9378)	0.0247
BLOCF (MMRM)	0.5609 (0.1296, 0.9921)	0.0109
BLOCF (ANCOVA)	0.5694 (0.1416, 0.9973)	0.0092
Wilcoxon rank sum test with LOCF		0.0401
Multiple imputation rank-based analysis		0.0334
Include site as a fixed effect rather than random	0.5262 (0.0830, 0.9694)	0.0201
Include region as a fixed effect instead of site	0.5303 (0.0705, 0.9900)	0.0239

Abbreviations: IR CD-LD=immediate carbidopa-levodopa, CI=confidence interval, PP=per protocol, MMRM=mixed model with repeated measures, ANCOVA=analysis of covariance, mITT=modified intent-to-treat, LOCF=last observation carried forward, BLOCF=baseline observation carried forward.

Source: Statistical Reviewer Analysis; *adpddp.xpt*, *adsl.xpt*

3.2.4.1.2 Supportive Analyses of Primary Endpoint

Supportive analyses were performed on the same MMRM as the primary efficacy analysis using per-protocol (PP) analysis set and both MMRM and ANCOVA were applied to the completer set (Table 7). The result in PP analysis set showed differences and it did not reach statistical significance (p=0.1718) which may be due to smaller samples (only 61.9% subjects were included in the PP analysis set).

Table 7. Supportive Analyses of Primary Efficacy Endpoint (“Good on” Time)

Analysis Set	IPX203 vs. IR CD-LD	
	LS Mean Difference (95% CI)	p-value
PP Analysis Set	0.3765 (-0.1644, 0.9173)	0.1718
Completers Set (MMRM)	0.6025 (0.1487, 1.0563)	0.0094
Completers Set (ANCOVA)	0.6178 (0.1682, 1.0675)	0.0072

Abbreviations: IR CD-LD=immediate carbidopa-levodopa, CI=confidence interval, PP=per protocol, MMRM=mixed model with repeated measures, ANCOVA=analysis of covariance.
Source: Statistical Reviewer Analysis; *adpdddep.xpt*, *adsl.xpt*

3.2.4.2 Key Secondary Endpoints

The key secondary endpoints are as follows: 1) change from baseline in “Off” time in hours per day, averaged over the PD diary days at the end of double-blind treatment period (Visit 7 or ET), 2) proportion of subjects with either “much improved” or “very much improved” in Patient Global Impression of Change (PGI-C) scores at the end of double-blind treatment period (Visit 7 or ET), 3) change from baseline in the MDS-UPDRS Part III at the end of double-blind treatment period (Visit 7 or ET), 4) change from baseline in the sum of MDS-UPDRS Part II and III at the end of double-blind treatment period (Visit 7 or ET).

3.2.4.2.1 “Off” Time

The first key secondary endpoint was the change from baseline to Visit 7 (Week 13)/ET in “Off” time. The LS mean change (SE) in “Off” time from baseline to Visit 7/ET was 0.3757 (0.1717) hours for IPX203 and 0.8568 (0.1713) hours for IR CD-LD, indicating less increase of “Off” time for IPX203 by -0.4812 hours (95% CI = (-0.9021, -0.0603), $p = 0.0252$), compared to IR CD-LD (Table 8).

Table 8. Key Secondary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)

Statistics (hour)	Randomized Treatment Group		Total (N=495)
	IPX203 (N=249)	IR CD-LD (N=246)	
Baseline visit			
N	249	246	495
Mean (SD)	3.945 (2.524)	4.018 (2.466)	3.982 (2.493)
Median (Q1, Q3)	3.67 (2.17, 5.67)	3.71 (2.17, 5.50)	3.67 (2.17, 5.67)
Min., Max.	0, 13.0	0, 13.67	0, 13.67
Visit 7 (Week 13)			
N	235	241	476
Mean (SD)	4.177 (2.833)	4.748 (2.884)	4.466 (2.870)
Median (Q1, Q3)	4.0 (2.0, 5.67)	4.33 (2.67, 6.50)	4.17 (2.50, 6.17)
Min., Max.	0, 16.83	0, 15.0	0, 16.83
Change at Visit 7 (Week 13) from baseline			
N	235	241	476
Mean (SD)	0.292 (2.235)	0.758 (2.901)	0.528 (2.601)
Median (Q1, Q3)	0 (-1.17, 1.50)	0.83 (-1.0, 2.417)	0.50 (-1.17, 1.92)
Min., Max.	-5.33, 8.0	-9.0, 8.0	-9.0, 8.0
LS Mean change (SE) at Week 12 from baseline	0.3757 (0.1717)	0.8568 (0.1713)	

Statistics (hour)	Randomized Treatment Group		Total (N=495)
	IPX203 (N=249)	IR CD-LD (N=246)	
LS Mean difference (95% CI) (IPX203 vs. IR CD-LD)	-0.4812 (-0.9021, -0.0603)		
p-value	0.0252		


Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, Max=maximum, Min=minimum, Q1=quarter 1, Q3=quarter 3, LS=least squares, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddep.xpt*, *adsl.xpt*

Figure 4 shows the LS mean change in “Off” time from baseline to each follow-up visit and its 95% CI during DBP by treatment group; red for IPX203-treated subjects and blue for IR CD-LD-treated subjects. The figure illustrates that the “Off” time increased more rapidly at Week 3 in IR CD-LD-treated subjects compared to the IPX203-treated subjects, and both groups tended to sustain the treatment effects through the end of double-blind treatment period.

Figure 4. Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)



Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, No.=number.

The LS means, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddep.xpt*, *adsl.xpt*

3.2.4.2.1.1 Sensitivity Analyses of Key Secondary Efficacy Endpoint (“Off” Time)

Sensitivity analyses were performed similar to the those of primary efficacy analysis. Sensitivity analyses of “Off” time for the IPX203 compared to the placebo group demonstrated that the impact from missing data did not change the conclusion for the primary analysis (Table 9).

Table 9. Sensitivity Analyses of Key Secondary Efficacy Endpoint (“Off” Time) in mITT Analysis Set

Sensitivity Analysis Type	IPX203 vs. IR CD-LD	
	LS Mean Difference (95% CI)	p-value
LOCF (MMRM)	-0.4538 (-0.8719, -0.0357)	0.0335
LOCF (ANCOVA)	-0.4521 (-0.8663, -0.0380)	0.0324
BLOCF (MMRM)	-0.5043 (-0.9136, -0.0951)	0.0158
BLOCF (ANCOVA)	-0.5009 (-0.9061, -0.0958)	0.0155
Wilcoxon rank sum test with LOCF		0.0318
Multiple imputation rank-based analysis		0.0345
Include site as a fixed effect rather than random	-0.4923 (-0.9150, -0.0696)	0.0225
Include region as a fixed effect instead of site	-0.4839 (-0.9181, -0.0496)	0.0291

Abbreviations: IR CD-LD=immediate carbidopa-levodopa, CI=confidence interval, PP=per protocol, mITT=modified intent-to-treat, MMRM=mixed model with repeated measures, ANCOVA=analysis of covariance, LOCF=last observation carried forward, BLOCF=baseline observation carried forward.

Source: Statistical Reviewer Analysis; *adpdddep.xpt*, *adsl.xpt*

3.2.4.2.1.2 Supportive Analyses of Key Secondary Efficacy Endpoint (“Off” Time)

Supportive analyses were performed on the same MMRM as the primary efficacy analysis using per-protocol (PP) analysis set and both MMRM and ANCOVA were applied to the completer set (Table 10). The result in PP analysis set showed differences and it did not reach statistical significance (p=0.0670).

Table 10. Supportive Analyses of Key Secondary Efficacy Endpoint (“Off” Time)

Analysis Set	IPX203 vs. IR CD-LD	
	LS Mean Difference (95% CI)	p-value
PP Analysis Set	-0.4835 (-1.0011, 0.0340)	0.0670
Completers Set (MMRM)	-0.5295 (-0.9592, -0.0999)	0.0158
Completers Set (ANCOVA)	-0.5213 (-0.9466, -0.0959)	0.0164

Abbreviations: IR CD-LD=immediate carbidopa-levodopa, CI=confidence interval, PP=per protocol, MMRM=mixed model with repeated measures, ANCOVA=analysis of covariance.

Source: Statistical Reviewer Analysis; *adpdddep.xpt*, *adsl.xpt*

3.2.4.2.2 PGI-C Scores

Table 11 summarized PGI-C scores at Visit 7/ET by the treatment group. At Visit 7/ET, 29.7% of subjects in the IPX203 group answered much or very much improvement in PGI-C scores

compared with 18.8% of subjects in the IR CD-LD group, and the difference of proportions was statistically significant ($p=0.0015$).

Table 11. Key Secondary Efficacy Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)

PGI-C Score	IPX203 (N=256) n (%)	IR CD-LD (N=250) n (%)
1: Very much worse	6 (2.4)	2 (0.8)
2: Much worse	22 (8.6)	19 (7.7)
3: Minimally worse	50 (19.6)	59 (23.8)
4: No change	32 (12.5)	53 (21.4)
5: Minimally improved	69 (27.1)	68 (27.4)
6: Much improved	68 (26.7)	46 (18.5)
7: Very much improved	8 (3.1)	1 (0.4)
Missing	1	2
Much or very much improved	76 (29.7)	47 (18.8)
Percent difference (95% CI)	10.9 (3.5, 18.3)	
p-value*	0.0015	

Abbreviations: PGI-C=patient global impression of change, ITT= intent-to-treat, IR CD-LD=immediate carbidopa-levodopa, n=number.

* p-value from Cochran-Mantel-Haenszel test stratified by pooled center comparing the proportion of much or very much improved subjects between the treatment groups.

Note: For subjects with missing PGI-C, the data were imputed as non-responders (i.e., not being “much improved” or “very much improved”).

Source: Statistical Reviewer Analysis; *adqseff.xpt*, *adsl.xpt*

3.2.4.2.3 MDS-UPDRS Part III

The LS mean change (SE) in the MDS-UPDRS Part III total score from baseline to Visit 7 (Week13)/ET was 0.7648 (0.7087) for IPX203 and 0.8110 (0.7153) for IR CD-LD. The LS mean difference between two groups was -0.0461 (95% CIs = (-1.7945, 1.7022), $p = 0.9587$), and it did not reach a statistical significance (Table 12). Hence, no further analysis was conducted for the rest of secondary endpoints listed in sequential hierarchical order.

Table 12. Key Secondary Efficacy Endpoint: Change from Baseline to Visit7/ET in MDS-UPDRS Part III during DBP by Randomized Treatment Group (ITT Analysis Set)

Statistics (hour)	Randomized Treatment Group		
	IPX203 (N=256)	IR CD-LD (N=250)	Total (N=506)
Baseline visit			
N	256	250	506
Mean (SD)	26.926 (16.623)	27.036 (16.835)	26.980 (16.712)
Median (Q1, Q3)	24.0 (14.0, 35.0)	24.0 (14.0, 35.0)	24.0 (14.0, 35.0)
Min., Max.	1.0, 111.0	4.0, 97.0	1.0, 111.0

Statistics (hour)	Randomized Treatment Group		
	IPX203 (N=256)	IR CD-LD (N=250)	Total (N=506)
Visit 7 (Week 13)			
N	254	249	503
Mean (SD)	27.756 (17.745)	27.968 (16.635)	27.861 (17.188)
Median (Q1, Q3)	23.0 (15.0, 36.0)	25.0 (15.0, 37.0)	25.0 (15.0, 37.0)
Min., Max.	1.0, 112.0	2.0, 97.0	1.0, 112.0
Change at Visit 7 (Week 13) from baseline			
N	254	249	503
Mean (SD)	1.075 (11.074)	0.912 (10.097)	0.994 (10.591)
Median (Q1, Q3)	0 (-5.0, 6.0)	1.0 (-4.0, 6.0)	0 (-4.0, 6.0)
Min., Max.	-30.0, 49.0	-36.0, 33.0	-36.0, 49.0
LS Mean change (SE) at Week 12 from baseline	0.7648 (0.7087)	0.8110 (0.7153)	
LS Mean difference (95% CI) (IPX203 vs. IR CD-LD)	-0.0461 (-1.7945, 1.7022)		
p-value	0.9587		

Abbreviations: DBP=double-blind treatment period, ET=early termination, MDS-UPDRS=Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale, ITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, Min=minimum, Max=maximum, Q1=quarter 1, Q3=quarter 3, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adqseff.xpt*, *adsl.xpt*

3.3 Evaluation of Safety

This review does not evaluate safety. Please refer to the clinical review for an evaluation of safety.

4 FINDINGS IN SPECIAL/SUBGROUP POPULATIONS

This section contains the results of reviewer's subgroup analyses. Subgroup analyses were analyzed for mITT population using the MMRM to evaluate the effect of important subgroups. Each subgroup result was also displayed in figures.

Table 13. Subgroup Analyses of Primary Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)

Subgroup		Treatment Arm	Sample Size (N)	Mean at Baseline (SD)	LS Mean Difference from Baseline (SE)	LS Mean Difference from Placebo (95% CI)
Age Group	< 65 years	IR CD-LD	90	12.35(2.74)	-1.746 (0.275)	--
		IPX203	97	12.23(2.87)	-0.398 (0.269)	1.348 (0.616, 2.079)
	≥ 65 years	IR CD-LD	156	11.36(2.71)	-0.570 (0.231)	--
		IPX203	152	11.32(2.94)	-0.611 (0.236)	-0.041(-0.598,0.517)
Gender	Female	IR CD-LD	72	11.67(2.68)	-1.004 (0.301)	--
		IPX203	97	11.33(2.92)	-0.678 (0.260)	0.326 (-0.426,1.078)
	Male	IR CD-LD	174	11.75(2.80)	-1.031 (0.214)	--
		IPX203	152	11.89(2.95)	-0.357 (0.231)	0.674 (0.103, 1.244)
Race	Caucasian	IR CD-LD	239	11.71(2.77)	-0.989 (0.184)	--
		IPX203	237	11.67 (3.0)	-0.474 (0.187)	0.515 (0.061, 0.969)
	Non-Caucasian	IR CD-LD	7	12.21(2.32)	-1.544 (1.194)	--
		IPX203	12	11.76(1.62)	-1.634 (1.016)	-0.089(-2.980,2.802)
Region	North America	IR CD-LD	132	11.88(2.68)	-1.175 (0.255)	--
		IPX203	117	11.97(2.71)	-0.389 (0.270)	0.786 (0.193, 1.379)
	Europe	IR CD-LD	114	11.54(2.85)	-0.877 (0.267)	--
		IPX203	132	11.41(3.13)	-0.60 (0.250)	0.277 (-0.389,0.743)
Ethnicity	Hispanic or Latino	IR CD-LD	31	11.79(2.54)	-0.055 (0.485)	--
		IPX203	32	11.88(2.25)	-0.588 (0.481)	-0.533(-1.899,0.832)
	Not Hispanic or Latino	IR CD-LD	211	11.70(2.80)	-1.10 (0.194)	--
		IPX203	216	11.63(3.04)	-0.457 (0.193)	0.643 (0.167, 1.119)
Concomitant Medications	Amantadine	IR CD-LD	24	10.79(2.70)	-0.849 (0.486)	--
		IPX203	28	11.34(2.94)	0.357 (0.453)	1.206 (-0.132,2.544)
	Selective MAOB inhibitors	IR CD-LD	76	12.03(2.76)	-1.091 (0.319)	--
		IPX203	88	12.12(2.83)	-0.292 (0.298)	0.799 (0.030, 1.568)
	Anticholinergic PD medications	IR CD-LD	9	10.87(3.25)	-0.335 (0.916)	--
		IPX203	13	11.29(3.03)	-0.952 (0.866)	-0.617(-2.182,0.948)
	Dopamine agonists	IR CD-LD	116	11.88(2.77)	-1.011 (0.277)	--
		IPX203	142	11.71(3.22)	-0.455 (0.256)	0.556 (-0.06, 1.173)
Weight	< 75 kg	IR CD-LD	227	11.63(2.77)	-0.962 (0.192)	--
		IPX203	231	11.64(2.96)	-0.468 (0.193)	0.494 (0.027, 0.960)
	≥ 75 kg	IR CD-LD	92	11.38(2.78)	-0.822 (0.261)	--
		IPX203	111	11.26(3.02)	-0.554 (0.241)	0.268 (-0.433,0.969)
BMI	< 25 kg/m ²	IR CD-LD	154	11.93(2.73)	-1.134 (0.232)	--
		IPX203	137	11.98(2.85)	-0.406 (0.247)	0.728 (0.132, 1.325)
	≥ 25 kg/m ²	IR CD-LD	83	11.63 (3.0)	-1.110 (0.292)	--
		IPX203	79	11.63(3.32)	-0.403 (0.305)	0.707 (-0.127,1.541)
PD duration at screening	< 8 years	IR CD-LD	163	11.77(2.64)	-0.960 (0.218)	--
		IPX203	169	11.67(2.76)	-0.529 (0.218)	0.430 (-0.10, 0.961)
	≥ 8 years	IR CD-LD	122	11.64(2.90)	-1.181 (0.249)	--
		IPX203	123	11.86(2.73)	-0.413 (0.249)	0.769 (0.119, 1.419)
Age of PD onset	< 65 years	IR CD-LD	124	11.81(2.62)	-0.879 (0.246)	--
		IPX203	126	11.48(3.14)	-0.547 (0.247)	0.332 (-0.297,0.962)
	≥ 65 years	IR CD-LD	180	11.90(2.71)	-1.290 (0.202)	--
		IPX203	191	11.80(2.98)	-0.454 (0.199)	0.835 (0.330, 1.341)
“Good On” time at entry	< 9 h/day	IR CD-LD	66	11.23(2.84)	-0.269 (0.356)	--
		IPX203	58	11.25(2.81)	-0.737 (0.381)	-0.468 (-1.426, 0.49)
	< 9 h/day	IR CD-LD	96	10.69(2.68)	-1.193 (0.271)	--
		IPX203	96	10.53(3.29)	-0.098 (0.277)	1.095 (0.350, 1.839)


Subgroup	Treatment Arm	Sample Size (N)	Mean at Baseline (SD)	LS Mean Difference from Baseline (SE)	LS Mean Difference from Placebo (95% CI)
≥ 9 h/day	IR CD-LD	150	12.39(2.61)	-0.876 (0.218)	--
	IPX203	153	12.39(2.45)	-0.701 (0.216)	0.175 (-0.389, 0.74)
“Off” time at entry	IR CD-LD	128	11.92(2.76)	-0.405 (0.256)	--
	IPX203	121	11.96(2.78)	-0.304 (0.265)	0.101 (-0.534, 0.736)
≥ 6 h/day	IR CD-LD	118	11.51(2.76)	-1.656 (0.226)	--
	IPX203	128	11.40(3.07)	-0.641 (0.222)	1.015 (0.413, 1.617)

Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddep.xpt*, *adsl.xpt*

Figure 5. Forest Plot of Subgroup Analysis for Primary Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set)



Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, n=number, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddep.xpt*, *adsl.xpt*

Table 14. Subgroup Analyses of Key Secondary Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)

Subgroup		Treatment Arm	Sample Size (N)	Mean at Baseline (SD)	LS Mean Difference from Baseline (SE)	LS Mean Difference from Placebo (95% CI)
Age Group	< 65 years	IR CD-LD	90	3.89 (2.42)	1.316 (0.266)	--
		IPX203	97	4.04 (2.62)	0.249 (0.260)	-1.067(-1.782,-0.351)
	≥ 65 years	IR CD-LD	156	4.10 (2.49)	0.568 (0.207)	--
		IPX203	152	3.88 (2.47)	0.443 (0.211)	-0.125(-0.654,0.404)
Gender	Female	IR CD-LD	72	3.95 (2.43)	0.811 (0.276)	--
		IPX203	97	4.15 (2.34)	0.513 (0.239)	-0.298(-0.984,0.389)
	Male	IR CD-LD	174	4.05 (2.49)	0.851 (0.205)	--
		IPX203	152	3.82 (2.64)	0.265 (0.222)	-0.586(-1.135,-0.037)
Race	Caucasian	IR CD-LD	239	3.98 (2.46)	0.822 (0.172)	--
		IPX203	237	3.97 (2.54)	0.377 (0.175)	-0.445(-0.878,-0.012)
	Non-Caucasian	IR CD-LD	7	5.23 (2.60)	1.103 (0.804)	--
		IPX203	12	3.49 (2.17)	0.292 (0.645)	-0.810 (-2.96, 1.339)
Region	North America	IR CD-LD	132	3.66 (2.22)	1.113 (0.224)	--
		IPX203	117	3.47 (2.31)	0.217 (0.237)	-0.896(-1.449,-0.343)
	Europe	IR CD-LD	114	4.43 (2.67)	0.584 (0.259)	--
		IPX203	132	4.36 (2.64)	0.492 (0.242)	-0.091(-0.733, 0.551)
Ethnicity	Hispanic or Latino	IR CD-LD	31	3.06 (2.14)	0.993 (0.580)	--
		IPX203	32	2.86 (2.49)	0.642 (0.585)	-0.351(-1.533, 0.831)
	Not Hispanic or Latino	IR CD-LD	211	4.16 (2.45)	0.786 (0.179)	--
		IPX203	216	4.12 (2.49)	0.342 (0.179)	-0.444(-0.903, 0.015)
Concomitant Medications	Amantadine	IR CD-LD	24	4.17 (2.47)	0.821 (0.465)	--
		IPX203	28	3.91 (2.37)	0.255 (0.434)	-0.566(-1.845, 0.713)
	Selective MAOB inhibitors	IR CD-LD	76	3.89 (2.44)	0.757 (0.296)	--
		IPX203	88	3.85 (2.49)	0.531 (0.277)	-0.226(-0.917, 0.465)
	Anticholinergic PD medications	IR CD-LD	9	3.69 (1.88)	-0.949(0.665)	--
		IPX203	13	4.32 (2.49)	-0.195(0.619)	0.754 (-0.687, 2.197)
	Dopamine agonists	IR CD-LD	116	4.29 (2.47)	0.735 (0.250)	--
		IPX203	142	4.06 (2.63)	0.283 (0.229)	-0.453(-1.038, 0.133)
	Others	IR CD-LD	227	4.09 (2.49)	0.835 (0.181)	--
		IPX203	231	3.93 (2.51)	0.378 (0.181)	-0.456(-0.897,-0.016)
Weight	< 75 kg	IR CD-LD	92	4.25 (2.45)	0.864 (0.264)	--
		IPX203	111	4.26 (2.54)	0.531 (0.244)	-0.333(-1.005, 0.339)
	≥ 75 kg	IR CD-LD	154	3.88 (2.47)	0.817 (0.216)	--
		IPX203	137	3.69 (2.50)	0.210 (0.229)	-0.607(-1.165,-0.049)
BMI	< 25 kg/m ²	IR CD-LD	83	4.10 (2.47)	0.883 (0.264)	--
		IPX203	79	4.02 (2.62)	0.284 (0.276)	-0.599(-1.354, 0.155)
	≥ 25 kg/m ²	IR CD-LD	163	3.98 (2.47)	0.802 (0.207)	--
		IPX203	169	3.91 (2.49)	0.409 (0.207)	-0.393(-0.908, 0.122)
PD duration at screening	< 8 years	IR CD-LD	122	4.11 (2.39)	1.074 (0.239)	--
		IPX203	123	3.96 (2.46)	0.106 (0.239)	-0.968 (-1.59, -0.345)
	≥ 8 years	IR CD-LD	124	3.93 (2.55)	0.592 (0.226)	--
		IPX203	126	3.93 (2.59)	0.577 (0.227)	-0.015(-0.602, 0.572)
Age of PD onset	< 65 years	IR CD-LD	180	4.03 (2.47)	1.089 (0.197)	--
		IPX203	191	3.91 (2.58)	0.429 (0.194)	-0.660(-1.147,-0.173)
	≥ 65 years	IR CD-LD	66	3.98 (2.48)	0.089 (0.305)	--
		IPX203	58	4.07 (2.33)	0.218 (0.329)	0.129 (-0.722, 0.98)
“Good On”	< 9 h/day	IR CD-LD	96	4.65 (2.42)	0.985 (0.250)	--


Subgroup	Treatment Arm	Sample Size (N)	Mean at Baseline (SD)	LS Mean Difference from Baseline (SE)	LS Mean Difference from Placebo (95% CI)
time at entry	IPX203	96	4.32 (2.67)	0.151 (0.253)	-0.833(-1.535,-0.131)
	IR CD-LD	150	3.62 (2.42)	0.727 (0.212)	--
	IPX203	153	3.71 (2.40)	0.469 (0.211)	-0.258(-0.794, 0.279)
“Off” time at entry	IR CD-LD	128	3.46 (2.32)	0.306 (0.228)	--
	IPX203	121	3.24 (2.21)	0.269 (0.236)	-0.037(-0.621, 0.548)
	IR CD-LD	118	4.63 (2.48)	1.404 (0.223)	--
	IPX203	128	4.61 (2.63)	0.395 (0.218)	-1.009(-1.594,-0.424)

Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddp.xpt*, *adsl.xpt*

Figure 6. Forest Plot of Subgroup Analysis for Key Secondary Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set)



Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, n=number, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpddp.xpt*, *adsl.xpt*

Table 15. Subgroup Analyses of Key Secondary Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)

	Subgroup	Treatment Arm	Much or very much improved	Percent Difference (95% CI)
Age Group	< 65 years	IR CD-LD	17 (18.5)	--
		IPX203	35 (35.0)	16.5 (4.3, 28.8)
	≥ 65 years	IR CD-LD	30 (19.0)	--
		IPX203	41 (26.3)	7.3 (-1.9, 16.5)
Gender	Female	IR CD-LD	18 (24.7)	--
		IPX203	25 (25.8)	1.1 (-12.1, 14.3)
	Male	IR CD-LD	29 (16.4)	--
		IPX203	51 (32.1)	15.7 (6.6, 24.8)
Race	Caucasian	IR CD-LD	46 (19.0)	--
		IPX203	72 (29.5)	10.5 (2.9, 18.1)
	Non-Caucasian	IR CD-LD	1 (12.5)	--
		IPX203	4 (33.3)	20.8 (-14.3, 56.0)
Region	North America	IR CD-LD	29 (21.6)	--
		IPX203	46 (37.7)	16.1 (5.0, 27.1)
	Europe	IR CD-LD	18 (15.5)	--
		IPX203	30 (22.4)	6.9 (-2.8, 16.5)
Ethnicity	Hispanic or Latino	IR CD-LD	11 (35.5)	--
		IPX203	11 (34.4)	-1.1 (-24.7, 22.4)
	Not Hispanic or Latino	IR CD-LD	36 (16.7)	--
		IPX203	65 (29.1)	12.4 (4.6, 20.2)
Concomitant Medications	Amantadine	IR CD-LD	2 (8.3)	--
		IPX203	11 (37.9)	29.6 (8.8, 50.4)
	Selective MAOB inhibitors	IR CD-LD	13 (16.7)	--
		IPX203	24 (26.7)	10.0 (-2.3, 22.3)
	Anticholinergic PD medications	IR CD-LD	2 (22.2)	--
		IPX203	2 (15.4)	-6.8 (-40.3, 26.7)
	Dopamine agonists	IR CD-LD	22 (18.5)	--
		IPX203	44 (30.3)	11.9 (1.6, 22.1)
	Others	IR CD-LD	43 (18.7)	--
		IPX203	68 (28.6)	9.9 (2.2, 17.5)
Weight	< 75 kg	IR CD-LD	18 (19.1)	--
		IPX203	29 (25.7)	6.5 (-4.8, 17.8)
	≥ 75 kg	IR CD-LD	29 (18.6)	--
		IPX203	46 (32.4)	13.8 (4.0, 23.6)
BMI	< 25 kg/m ²	IR CD-LD	17 (19.8)	--
		IPX203	21 (26.2)	6.5 (-6.3, 19.3)
	≥ 25 kg/m ²	IR CD-LD	30 (18.3)	--
		IPX203	54 (30.9)	12.6 (3.5, 21.6)
PD duration at screening	< 8 years	IR CD-LD	30 (24.2)	--
		IPX203	43 (34.4)	10.2 (-1.0, 21.4)
	≥ 8 years	IR CD-LD	17 (13.5)	--
		IPX203	33 (25.2)	11.7 (2.2, 21.2)
Age of PD onset	< 65 years	IR CD-LD	30 (16.3)	--
		IPX203	64 (33.0)	16.7 (8.2, 25.2)
	≥ 65 years	IR CD-LD	17 (25.8)	--
		IPX203	12 (19.3)	-6.4 (-20.8, 8.0)
“Good On” time at entry	< 9 h/day	IR CD-LD	18 (18.6)	--
		IPX203	32 (33.3)	14.8 (2.6, 27.0)
	≥ 9 h/day	IR CD-LD	29 (18.9)	--

Subgroup		Treatment Arm	Much or very much improved	Percent Difference (95% CI)
		IPX203	44 (27.5)	8.5 (-0.7, 17.8)
“Off” time at entry	< 6 h/day	IR CD-LD	24 (18.7)	--
		IPX203	32 (25.4)	6.6 (-3.5, 16.8)
	≥ 6 h/day	IR CD-LD	23 (18.8)	--
		IPX203	44 (33.8)	15.0 (4.3, 25.7)


Abbreviations: PGI-C=patient global impression of change, ITT= intent-to-treat, IR CD-LD=immediate carbidopa-levodopa, n=number.

* p-value from Cochran-Mantel-Haenszel test stratified by pooled center comparing the proportion of much or very much improved subjects between the treatment groups.

Note: For subjects with missing PGI-C, the data will be imputed as non-responders (i.e., not being “much improved” or “very much improved”).

Source: Statistical Reviewer Analysis; *adqseff.xpt*, *adsl.xpt*

Figure 7. Forest Plot of Subgroup Analysis for Key Secondary Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set)



Abbreviations: PGI-C=patient global impression of change, ITT= intent-to-treat, IR CD-LD=immediate carbidopa-levodopa, n=number, %=percent.

Note: For subjects with missing PGI-C, the data will be imputed as non-responders (i.e., not being “much improved” or “very much improved”).

Source: Statistical Reviewer Analysis; *adqseff.xpt*, *adsl.xpt*

Age group (< 65; ≥ 65 years), gender (Female; Male), race (Caucasian; Non-Caucasian), region (North America; Europe), ethnicity (Hispanic or Latino; Not Hispanic or Latino), concomitant medications (Amantadine; Selective MAOB inhibitors; Anticholinergic PD medications; Dopamine agonists; others), weight (< 75; ≥ 75 kg), BMI (< 25 kg/m² ; ≥ 25 kg/m²), PD duration (< 8; ≥ 8 years), age of PD onset (<65 ; ≥ 65 years), “Good on” time at entry (< 9 h/day; ≥ 9h/day), “off” time at entry (< 6 h/day; ≥ 6 h/day)

The primary efficacy analysis on “Good on” time, the first key secondary efficacy analysis on “Off” time, and the second key secondary efficacy analysis on PGI-C showed large differences between age of PD onset subgroups (<65 vs. ≥ 65 years).

All other subgroup analysis results showed consistent patterns with overall efficacy analysis results.

5 SUMMARY AND CONCLUSIONS

5.1 Statistical Issues

For “Good on” time, “Off” time and PGI-C, the treatment effect of IPX203 may be different between the age of PD onset subgroups (<65 vs. $\geq$ 65 years). Because the confidence intervals of two groups are overlapped, the treatment effect of IPX203 between groups may not be significantly apart.

5.2 Collective Evidence

Study IPX203-B16-02 showed a statistically significant difference between IPX203 and IR CD-LD in primary (change in “Good on” time from baseline to Visit7/ET) and two key secondary efficacy endpoints (change in “Off” time from baseline to Visit7/ET and the proportion of subjects with either “much improved” or “very much improved” in PGI-C scores at Visit7/ET). However, the treatment effect may be different between the age of PD onset subgroups.


5.3 Conclusions and Recommendations

There are findings to support a significant treatment effect of IPX203 compared to IR CD-LD in the treatment of CD-LD experienced subjects with Parkinson’s disease who have motor fluctuations, measured by “Good on” time, “Off” time and patient global impression of change (PGI-C) scores.


6 Appendix I : Model Diagnostics

1. Model Diagnostics of Efficacy Analysis (Mixed Model for Repeated Measures) on the primary endpoint (Change in “Good on” Time)

1.1 Residual analysis: To check stability of variance and normal distribution of residuals



Tests for Normality				
Test	Statistic		p Value	
Shapiro-Wilk	W	0.98793	Pr < W	<0.0001
Kolmogorov-Smirnov	D	0.035697	Pr > D	<0.0100
Cramer-von Mises	W-Sq	0.571722	Pr > W-Sq	<0.0050
Anderson-Darling	A-Sq	3.512417	Pr > A-Sq	<0.0050



***Note:** The data is not normally distributed, hence, the reviewer performed non-parametric analysis (Wilcoxon rank sum test) for sensitivity analysis.

1.2. Influence analysis: To check stability of the model when a particular data point is removed.

Influence Diagnostics for Levels of USUBJID												
Unique Subject Identifier	Number of Observations in Level	Iterations	PRESS Statistic	Cook's D	MDFFITS	COVRATIO	COVTR ACE	Cook's D CovParms	MDFFITS CovParms	COVTRATIO CovParms	COVTR ACE CovParms	Restricted Likelihood Distance
(b) (6)	3	5	0.253	0.000	0.000	1.014	0.014	0.000	0.000	0.984	0.017	0.000
IPX203-B16-02-	3	5	1.277	0.000	0.000	1.023	0.023	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02-	1	2	1.241	0.000	0.000	1.011	0.011	0.001	0.001	1.018	0.018	0.002
IPX203-B16-02-	3	2	12.362	0.001	0.001	1.027	0.027	0.004	0.004	1.047	0.046	0.008
IPX203-B16-02-	3	2	79.722	0.005	0.005	0.992	0.008	0.069	0.071	0.986	0.014	0.107
IPX203-B16-02-	3	2	2.019	0.001	0.000	1.025	0.025	0.002	0.002	1.042	0.041	0.006
IPX203-B16-02-	3	2	34.726	0.002	0.002	1.014	0.014	0.007	0.007	1.021	0.021	0.020
IPX203-B16-02-	3	2	7.661	0.001	0.001	1.030	0.030	0.003	0.003	1.045	0.044	0.009
IPX203-B16-02-	3	2	7.554	0.001	0.001	1.024	0.024	0.003	0.003	1.042	0.041	0.008
IPX203-B16-02-	3	2	8.97	0.001	0.001	1.021	0.021	0.003	0.003	1.034	0.034	0.011
IPX203-B16-02-	3	5	1.852	0.000	0.000	1.014	0.014	0.000	0.000	0.996	0.004	0.002
IPX203-B16-02-	3	2	3.978	0.001	0.001	1.029	0.029	0.002	0.002	1.038	0.038	0.007
IPX203-B16-02-	3	2	110.177	0.010	0.010	0.934	0.067	0.232	0.246	0.874	0.131	0.314
IPX203-B16-02-	3	2	6.183	0.002	0.002	1.019	0.019	0.005	0.005	1.029	0.029	0.018
IPX203-B16-02-	3	5	1.327	0.000	0.000	1.013	0.013	0.000	0.000	0.991	0.010	0.001
IPX203-B16-02-	3	2	5.035	0.000	0.000	1.023	0.023	0.003	0.003	1.043	0.042	0.005
IPX203-B16-02-	1	2	8.286	0.003	0.003	1.013	0.014	0.003	0.003	0.994	0.006	0.021
IPX203-B16-02-	1	2	15.867	0.001	0.001	0.990	0.010	0.004	0.004	0.975	0.025	0.011
IPX203-B16-02-	3	2	31.951	0.005	0.005	1.007	0.007	0.054	0.055	1.007	0.008	0.087
IPX203-B16-02-	3	2	8.247	0.001	0.001	1.034	0.033	0.007	0.006	1.059	0.058	0.013
IPX203-B16-02-	3	2	4.867	0.002	0.002	1.020	0.020	0.004	0.004	1.032	0.032	0.015
IPX203-B16-02-	1	2	2.71	0.001	0.001	1.015	0.015	0.003	0.003	1.030	0.030	0.006
IPX203-B16-02-	1	2	38.818	0.003	0.003	0.968	0.032	0.020	0.021	0.920	0.082	0.041
IPX203-B16-02-	3	2	2.929	0.001	0.001	1.025	0.025	0.002	0.002	1.044	0.044	0.007
IPX203-B16-02-	3	2	40.844	0.003	0.003	1.011	0.011	0.010	0.010	1.013	0.013	0.029
IPX203-B16-02-	3	2	12.035	0.002	0.002	1.023	0.023	0.006	0.006	1.026	0.026	0.019
IPX203-B16-02-	3	2	5.407	0.001	0.001	1.019	0.019	0.004	0.004	1.030	0.030	0.014
IPX203-B16-02-	3	2	31.441	0.002	0.002	0.995	0.005	0.022	0.022	0.979	0.020	0.039
IPX203-B16-02-	3	2	23.041	0.001	0.001	1.004	0.004	0.016	0.016	0.999	0.000	0.021
IPX203-B16-02-	3	2	19.226	0.001	0.001	1.007	0.007	0.012	0.012	1.009	0.010	0.018
IPX203-B16-02-	3	2	95.826	0.003	0.003	0.958	0.042	0.081	0.092	0.879	0.120	0.109
IPX203-B16-02-	3	2	15.705	0.000	0.000	1.012	0.012	0.010	0.010	1.021	0.021	0.013
IPX203-B16-02-	3	2	42.075	0.001	0.001	0.991	0.009	0.031	0.033	0.961	0.037	0.039
IPX203-B16-02-	3	2	7.333	0.001	0.001	1.024	0.023	0.003	0.003	1.062	0.061	0.007
IPX203-B16-02-	3	2	5.383	0.001	0.001	1.020	0.019	0.004	0.004	1.033	0.033	0.013
IPX203-B16-02-	3	2	80.536	0.014	0.014	0.944	0.057	0.315	0.338	0.860	0.146	0.431
IPX203-B16-02-	3	2	37.477	0.003	0.003	1.003	0.003	0.016	0.016	0.979	0.021	0.042
IPX203-B16-02-	3	2	19.706	0.004	0.004	1.003	0.003	0.033	0.034	1.012	0.012	0.061
IPX203-B16-02-	3	2	1.117	0.000	0.000	1.035	0.035	0.003	0.003	1.061	0.060	0.005
IPX203-B16-02-	1	2	23.353	0.003	0.003	0.984	0.017	0.009	0.010	0.940	0.061	0.029
IPX203-B16-02-	3	2	5.222	0.001	0.001	1.038	0.038	0.011	0.010	1.093	0.091	0.013
IPX203-B16-02-	3	2	2.902	0.000	0.000	1.031	0.030	0.003	0.003	1.054	0.053	0.006
IPX203-B16-02-	3	5	0.489	0.000	0.000	1.013	0.013	0.000	0.000	0.986	0.014	0.000
IPX203-B16-02-	2	2	13.904	0.001	0.001	1.007	0.007	0.003	0.003	1.005	0.005	0.012
IPX203-B16-02-	3	2	9.228	0.002	0.002	1.020	0.020	0.006	0.006	1.034	0.034	0.018
IPX203-B16-02-	1	2	0.39	0.000	0.000	1.014	0.014	0.001	0.001	1.027	0.027	0.002
IPX203-B16-02-	3	2	23.416	0.002	0.002	1.016	0.016	0.005	0.005	1.008	0.008	0.017
IPX203-B16-02-	3	2	4.79	0.001	0.001	1.035	0.034	0.005	0.005	1.072	0.070	0.010
IPX203-B16-02-	3	2	19.343	0.002	0.002	1.012	0.012	0.007	0.007	1.008	0.008	0.019
IPX203-B16-02-	3	2	15.754	0.001	0.001	1.021	0.021	0.003	0.003	1.021	0.021	0.010
IPX203-B16-02-	1	2	0.952	0.000	0.000	1.014	0.014	0.002	0.002	1.037	0.037	0.003
IPX203-B16-02-	3	2	9.15	0.002	0.002	1.022	0.022	0.006	0.006	1.030	0.030	0.018
IPX203-B16-02-	3	2	32.651	0.003	0.003	1.015	0.015	0.017	0.017	1.031	0.031	0.035
IPX203-B16-02-	3	2	8.131	0.000	0.000	1.024	0.023	0.002	0.002	1.034	0.034	0.006
IPX203-B16-02-	3	2	18.055	0.001	0.001	1.019	0.019	0.005	0.005	1.027	0.027	0.011
IPX203-B16-02-	3	2	9.119	0.002	0.002	1.016	0.016	0.006	0.006	1.023	0.023	0.017
IPX203-B16-02-	2	2	16	0.001	0.001	1.011	0.011	0.002	0.002	1.010	0.010	0.010
IPX203-B16-02-	3	2	1.977	0.001	0.001	1.025	0.025	0.002	0.002	1.038	0.037	0.006
IPX203-B16-02-	3	3	75.681	0.020	0.021	0.891	0.110	1.083	1.248	0.778	0.236	1.349
IPX203-B16-02-	3	2	16.786	0.003	0.003	1.007	0.007	0.013	0.013	0.998	0.002	0.031
IPX203-B16-02-	3	2	5.707	0.001	0.001	1.034	0.034	0.006	0.006	1.074	0.072	0.013
IPX203-B16-02-	3	2	1.163	0.000	0.000	1.029	0.029	0.003	0.003	1.059	0.058	0.005
IPX203-B16-02-	3	2	14.528	0.001	0.001	1.018	0.018	0.004	0.004	1.017	0.017	0.009
IPX203-B16-02-	3	2	53.188	0.002	0.002	0.998	0.002	0.014	0.014	0.974	0.025	0.030
IPX203-B16-02-	3	2	5.659	0.001	0.001	1.032	0.032	0.003	0.003	1.053	0.052	0.007
IPX203-B16-02-	3	2	20.879	0.005	0.005	1.017	0.017	0.027	0.028	1.020	0.020	0.061
IPX203-B16-02-	3	2	6.03	0.001	0.001	1.025	0.025	0.003	0.003	1.036	0.036	0.009

IPX203-B16-02-	(b) (6)	3	2	20.663	0.002	0.002	1.014	0.014	0.008	0.008	1.003	0.003	0.022
IPX203-B16-02-		3	2	3.19	0.001	0.001	1.029	0.029	0.002	0.002	1.049	0.048	0.006
IPX203-B16-02-		3	2	33.373	0.002	0.002	1.009	0.010	0.012	0.013	0.985	0.014	0.030
IPX203-B16-02-		3	2	0.226	0.000	0.000	1.035	0.035	0.005	0.004	1.078	0.076	0.005
IPX203-B16-02-		2	2	55.077	0.004	0.004	0.971	0.029	0.035	0.037	0.905	0.096	0.067
IPX203-B16-02-		3	2	32.645	0.001	0.001	1.004	0.005	0.013	0.014	0.983	0.016	0.025
IPX203-B16-02-		3	2	0.769	0.000	0.000	1.042	0.042	0.009	0.008	1.096	0.093	0.011
IPX203-B16-02-		3	2	5.54	0.001	0.001	1.022	0.022	0.003	0.003	1.033	0.033	0.008
IPX203-B16-02-		3	2	51.176	0.004	0.004	1.009	0.009	0.011	0.011	0.998	0.002	0.042
IPX203-B16-02-		3	2	54.013	0.010	0.010	0.971	0.029	0.226	0.239	0.939	0.060	0.303
IPX203-B16-02-		3	5	1.163	0.000	0.000	1.013	0.013	0.000	0.000	0.988	0.012	0.001
IPX203-B16-02-		3	2	10.108	0.001	0.001	1.019	0.019	0.003	0.003	1.027	0.027	0.009
IPX203-B16-02-		3	2	13.639	0.002	0.002	1.009	0.009	0.009	0.009	1.013	0.013	0.023
IPX203-B16-02-		3	2	20.208	0.001	0.001	1.016	0.016	0.003	0.003	1.022	0.022	0.008
IPX203-B16-02-		3	2	6.32	0.001	0.001	1.023	0.022	0.004	0.004	1.039	0.039	0.011
IPX203-B16-02-		3	2	2.961	0.001	0.001	1.023	0.023	0.002	0.002	1.040	0.039	0.007
IPX203-B16-02-		3	2	5.841	0.000	0.000	1.027	0.026	0.003	0.003	1.037	0.037	0.005
IPX203-B16-02-		3	2	40.902	0.010	0.011	0.963	0.037	0.240	0.256	0.920	0.080	0.324
IPX203-B16-02-		3	2	3.545	0.001	0.001	1.026	0.026	0.003	0.003	1.044	0.043	0.008
IPX203-B16-02-		3	2	7.094	0.001	0.001	1.031	0.031	0.003	0.003	1.029	0.029	0.010
IPX203-B16-02-		3	2	10.741	0.001	0.001	1.019	0.019	0.003	0.003	1.028	0.027	0.008
IPX203-B16-02-		1	2	4.282	0.000	0.000	1.003	0.003	0.002	0.002	0.999	0.001	0.004
IPX203-B16-02-		3	2	10.272	0.001	0.001	1.021	0.021	0.004	0.004	1.022	0.022	0.008
IPX203-B16-02-		3	2	29.242	0.002	0.002	1.010	0.010	0.009	0.009	0.992	0.008	0.023
IPX203-B16-02-		3	2	42.015	0.005	0.005	1.016	0.016	0.042	0.042	1.034	0.035	0.075
IPX203-B16-02-		3	2	3.568	0.001	0.001	1.022	0.022	0.003	0.003	1.035	0.035	0.009
IPX203-B16-02-		3	5	3.903	0.000	0.000	1.022	0.022	0.001	0.001	1.015	0.015	0.003
IPX203-B16-02-		3	5	1.288	0.000	0.000	1.023	0.023	0.001	0.001	1.016	0.015	0.003
IPX203-B16-02-		3	5	4.999	0.000	0.000	1.022	0.022	0.001	0.001	1.014	0.014	0.004
IPX203-B16-02-		1	2	17.484	0.002	0.002	0.999	0.002	0.003	0.003	0.984	0.016	0.017
IPX203-B16-02-		3	5	0.992	0.000	0.000	1.013	0.013	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		3	5	1.425	0.000	0.000	1.013	0.013	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		1	2	25.468	0.003	0.003	0.992	0.008	0.012	0.012	0.974	0.026	0.030
IPX203-B16-02-		3	2	67.457	0.005	0.005	1.007	0.008	0.065	0.066	1.027	0.029	0.101
IPX203-B16-02-		2	2	3.68	0.001	0.001	1.020	0.020	0.001	0.001	1.028	0.028	0.005
IPX203-B16-02-		3	5	2.246	0.000	0.000	1.014	0.014	0.000	0.000	0.989	0.011	0.001
IPX203-B16-02-		3	2	3.954	0.001	0.001	1.033	0.033	0.003	0.002	1.036	0.036	0.009
IPX203-B16-02-		3	2	28.096	0.002	0.002	1.014	0.014	0.004	0.004	1.015	0.015	0.015
IPX203-B16-02-		3	2	4.664	0.001	0.001	1.033	0.033	0.005	0.004	1.059	0.057	0.008
IPX203-B16-02-		2	2	1.39	0.000	0.000	1.018	0.018	0.002	0.002	1.032	0.031	0.003
IPX203-B16-02-		2	2	41.07	0.002	0.002	0.991	0.009	0.010	0.010	0.971	0.029	0.026
IPX203-B16-02-		3	2	28.742	0.004	0.004	1.035	0.035	0.022	0.021	1.060	0.059	0.051
IPX203-B16-02-		3	2	33.27	0.002	0.002	1.009	0.009	0.007	0.007	1.007	0.008	0.019
IPX203-B16-02-		3	2	7.03	0.001	0.001	1.031	0.031	0.004	0.004	1.053	0.052	0.011
IPX203-B16-02-		3	2	4.861	0.001	0.001	1.022	0.021	0.003	0.003	1.034	0.034	0.006
IPX203-B16-02-		3	2	1.885	0.000	0.000	1.029	0.029	0.003	0.003	1.051	0.050	0.005
IPX203-B16-02-		3	2	11.936	0.002	0.002	1.012	0.012	0.006	0.006	1.015	0.015	0.017
IPX203-B16-02-		1	2	3.055	0.000	0.000	1.006	0.006	0.000	0.000	1.012	0.012	0.002
IPX203-B16-02-		3	2	16.636	0.003	0.003	1.012	0.012	0.022	0.023	1.026	0.026	0.043
IPX203-B16-02-		3	2	43.069	0.007	0.007	0.976	0.024	0.103	0.107	0.943	0.057	0.154
IPX203-B16-02-		3	2	45.215	0.003	0.003	1.000	0.000	0.024	0.024	0.999	0.000	0.043
IPX203-B16-02-		3	2	7.865	0.002	0.002	1.013	0.013	0.006	0.007	1.018	0.018	0.020
IPX203-B16-02-		3	2	2.79	0.001	0.001	1.042	0.041	0.003	0.003	1.049	0.048	0.009
IPX203-B16-02-		3	2	10.701	0.001	0.001	1.030	0.029	0.004	0.004	1.045	0.044	0.010
IPX203-B16-02-		3	2	14.929	0.002	0.002	1.021	0.021	0.011	0.011	1.034	0.033	0.024
IPX203-B16-02-		3	5	0.447	0.000	0.000	1.012	0.012	0.000	0.000	0.986	0.014	0.000
IPX203-B16-02-		3	2	79.355	0.014	0.014	0.926	0.075	0.490	0.536	0.856	0.149	0.622
IPX203-B16-02-		3	2	3.181	0.000	0.000	1.025	0.025	0.003	0.003	1.037	0.037	0.006
IPX203-B16-02-		3	2	3.606	0.001	0.001	1.027	0.027	0.003	0.003	1.036	0.036	0.010
IPX203-B16-02-		3	2	2.672	0.001	0.001	1.023	0.023	0.002	0.002	1.037	0.037	0.007
IPX203-B16-02-		3	2	28.412	0.003	0.003	1.029	0.029	0.011	0.011	1.037	0.036	0.035
IPX203-B16-02-		3	2	6.106	0.000	0.000	1.023	0.022	0.003	0.003	1.038	0.038	0.005
IPX203-B16-02-		3	2	35.746	0.002	0.002	1.005	0.005	0.016	0.016	1.011	0.011	0.030
IPX203-B16-02-		3	2	8.312	0.002	0.002	1.016	0.016	0.006	0.006	1.025	0.025	0.018
IPX203-B16-02-		3	5	0.713	0.000	0.000	1.013	0.013	0.000	0.000	0.988	0.012	0.000
IPX203-B16-02-		3	2	6.587	0.002	0.002	1.048	0.047	0.012	0.011	1.101	0.098	0.024
IPX203-B16-02-		1	2	1.273	0.000	0.000	1.008	0.008	0.001	0.001	1.018	0.018	0.001
IPX203-B16-02-		3	2	39.969	0.004	0.004	0.995	0.005	0.022	0.023	0.960	0.040	0.050
IPX203-B16-02-		3	2	0.967	0.000	0.000	1.030	0.030	0.003	0.003	1.053	0.052	0.005
IPX203-B16-02-		3	2	20.417	0.001	0.001	1.020	0.020	0.003	0.003	1.033	0.032	0.010
IPX203-B16-02-		3	2	4.398	0.001	0.001	1.024	0.024	0.003	0.003	1.039	0.038	0.009
IPX203-B16-02-		3	2	7.988	0.001	0.001	1.028	0.028	0.003	0.003	1.050	0.049	0.008
IPX203-B16-02-		2	2	2.856	0.001	0.001	1.021	0.021	0.001	0.001	1.030	0.029	0.005
IPX203-B16-02-		1	2	0.138	0.000	0.000	1.010	0.010	0.001	0.001	1.021	0.021	0.001
IPX203-B16-02-		3	2	18.162	0.002	0.002	1.025	0.025	0.004	0.004	1.044	0.043	0.017
IPX203-B16-02-		3	2	78.559	0.004	0.004	1.006	0.007	0.046	0.047	1.015	0.016	0.074
IPX203-B16-02-		3	5	1.723	0.000	0.000	1.017	0.017	0.000	0.000	1.003	0.003	0.002
IPX203-B16-02-		3	2	38.4	0.009	0.010	0.964	0.035	0.213	0.226	0.918	0.083	0.292
IPX203-B16-02-		3	2	15.74	0.002	0.002	1.036	0.036	0.008	0.008	1.071	0.069	0.020
IPX203-B16-02-		1	2	0.656	0.000	0.000	1.012	0.012	0.001	0.001	1.028	0.027	0.002
IPX203-B16-02-		3	2	38.555	0.005	0.005	0.990	0.010	0.055	0.056	0.966	0.034	0.093
IPX203-B16-02-		3	2	12.526	0.001	0.001	1.021	0.021	0.003	0.003	1.031	0.030	0.010
IPX203-B16-02-		3	2	5.375	0.001	0.001	1.027	0.027	0.002	0.002	1.037	0.036	0.006
IPX203-B16-02-		3	2	14.007	0.003	0.002	1.032	0.032	0.020	0.019	1.084	0.083	0.035


IPX203-B16-02	(b) (6)	3	2	24.139	0.001	0.001	1.017	0.017	0.003	0.003	1.024	0.024	0.010
IPX203-B16-02		3	2	25.272	0.004	0.004	0.994	0.006	0.037	0.038	0.975	0.025	0.067
IPX203-B16-02		3	2	86.644	0.008	0.008	0.987	0.013	0.033	0.034	0.942	0.058	0.089
IPX203-B16-02		3	5	1.148	0.000	0.000	1.014	0.014	0.000	0.000	0.992	0.008	0.001
IPX203-B16-02		3	2	32.185	0.005	0.005	0.988	0.012	0.053	0.055	0.961	0.039	0.089
IPX203-B16-02		3	2	12.149	0.004	0.004	1.007	0.007	0.028	0.028	1.016	0.017	0.055
IPX203-B16-02		3	2	72.782	0.005	0.005	0.974	0.026	0.056	0.058	0.922	0.079	0.095
IPX203-B16-02		3	2	3.311	0.001	0.001	1.042	0.041	0.013	0.012	1.102	0.100	0.016
IPX203-B16-02		2	2	67.028	0.008	0.008	0.951	0.049	0.103	0.107	0.864	0.142	0.159
IPX203-B16-02		3	2	5.752	0.001	0.001	1.034	0.034	0.010	0.010	1.085	0.083	0.017
IPX203-B16-02		3	2	56.638	0.004	0.004	0.984	0.016	0.038	0.039	0.947	0.053	0.065
IPX203-B16-02		2	2	6.241	0.000	0.000	1.012	0.012	0.004	0.004	1.021	0.021	0.005
IPX203-B16-02		3	2	8.062	0.001	0.001	1.026	0.026	0.005	0.005	1.050	0.049	0.012
IPX203-B16-02		3	2	49.562	0.004	0.004	0.996	0.004	0.028	0.029	0.984	0.016	0.053
IPX203-B16-02		3	2	8.921	0.002	0.002	1.019	0.019	0.008	0.008	1.022	0.022	0.021
IPX203-B16-02		3	2	24.43	0.001	0.001	1.011	0.011	0.005	0.005	1.010	0.010	0.015
IPX203-B16-02		3	2	1.279	0.000	0.000	1.033	0.032	0.003	0.003	1.061	0.059	0.005
IPX203-B16-02		3	2	38.053	0.003	0.003	0.995	0.005	0.020	0.020	0.970	0.030	0.039
IPX203-B16-02		3	5	2.558	0.000	0.000	1.020	0.020	0.000	0.000	1.008	0.008	0.002
IPX203-B16-02		2	2	11.963	0.001	0.001	1.007	0.007	0.004	0.004	1.001	0.001	0.009
IPX203-B16-02		3	2	4.479	0.000	0.000	1.023	0.023	0.003	0.003	1.038	0.038	0.005
IPX203-B16-02		3	2	14.625	0.002	0.002	1.024	0.024	0.004	0.004	1.023	0.022	0.017
IPX203-B16-02		3	2	4.344	0.000	0.000	1.030	0.030	0.003	0.003	1.053	0.052	0.005
IPX203-B16-02		3	2	39.307	0.002	0.002	1.012	0.012	0.014	0.014	1.023	0.023	0.030
IPX203-B16-02		3	2	3.805	0.000	0.000	1.029	0.028	0.003	0.003	1.050	0.049	0.006
IPX203-B16-02		3	2	12.019	0.001	0.001	1.024	0.024	0.002	0.002	1.032	0.032	0.011
IPX203-B16-02		3	2	13.299	0.001	0.001	1.026	0.026	0.004	0.004	1.052	0.051	0.010
IPX203-B16-02		3	5	1.728	0.000	0.000	1.019	0.019	0.000	0.000	1.002	0.002	0.002
IPX203-B16-02		1	2	3.507	0.000	0.000	1.007	0.007	0.000	0.000	1.009	0.009	0.003
IPX203-B16-02		3	2	7.115	0.000	0.000	1.024	0.024	0.003	0.003	1.034	0.034	0.006
IPX203-B16-02		3	5	4.068	0.000	0.000	1.013	0.012	0.000	0.000	0.991	0.009	0.001
IPX203-B16-02		3	2	25.371	0.002	0.002	1.029	0.028	0.014	0.014	1.061	0.061	0.029
IPX203-B16-02		3	2	2.328	0.000	0.000	1.024	0.024	0.002	0.002	1.040	0.040	0.006
IPX203-B16-02		3	2	6.824	0.001	0.001	1.024	0.024	0.003	0.002	1.031	0.031	0.007
IPX203-B16-02		3	2	9.584	0.001	0.001	1.026	0.025	0.002	0.002	1.034	0.033	0.009
IPX203-B16-02		3	5	1.243	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	2.566	0.001	0.001	1.027	0.027	0.003	0.003	1.045	0.044	0.006
IPX203-B16-02		3	2	14.359	0.003	0.003	1.020	0.020	0.012	0.012	1.029	0.028	0.030
IPX203-B16-02		3	2	11.498	0.001	0.001	1.029	0.029	0.003	0.003	1.049	0.048	0.012
IPX203-B16-02		2	2	8.067	0.000	0.000	1.016	0.016	0.001	0.001	1.025	0.025	0.004
IPX203-B16-02		3	2	17.348	0.004	0.004	1.006	0.006	0.029	0.030	1.000	0.000	0.055
IPX203-B16-02		3	5	1.619	0.000	0.000	1.022	0.022	0.001	0.001	1.018	0.018	0.003
IPX203-B16-02		3	2	3.665	0.001	0.001	1.023	0.023	0.002	0.002	1.036	0.036	0.008
IPX203-B16-02		3	2	46.101	0.003	0.003	1.006	0.006	0.027	0.027	1.003	0.003	0.051
IPX203-B16-02		3	2	3.471	0.001	0.001	1.024	0.024	0.002	0.002	1.039	0.038	0.006
IPX203-B16-02		3	2	6.186	0.000	0.000	1.022	0.022	0.003	0.003	1.034	0.033	0.006
IPX203-B16-02		3	2	6.154	0.001	0.001	1.026	0.026	0.002	0.002	1.033	0.033	0.008
IPX203-B16-02		3	2	34.752	0.003	0.003	1.018	0.018	0.004	0.004	1.011	0.012	0.026
IPX203-B16-02		3	2	15.587	0.002	0.002	1.012	0.012	0.008	0.008	1.012	0.012	0.021
IPX203-B16-02		3	2	3.781	0.000	0.000	1.031	0.030	0.004	0.003	1.057	0.056	0.005
IPX203-B16-02		3	2	5.973	0.001	0.001	1.023	0.023	0.003	0.003	1.031	0.030	0.009
IPX203-B16-02		3	2	75.09	0.013	0.013	0.966	0.033	0.340	0.361	0.947	0.049	0.447
IPX203-B16-02		3	2	14.911	0.000	0.000	1.020	0.020	0.003	0.003	1.036	0.035	0.006
IPX203-B16-02		3	2	37.368	0.001	0.001	1.008	0.008	0.006	0.006	1.018	0.018	0.013
IPX203-B16-02		3	2	39.995	0.002	0.002	1.014	0.014	0.031	0.031	1.014	0.015	0.044
IPX203-B16-02		3	2	13.829	0.001	0.001	1.013	0.013	0.005	0.005	1.022	0.021	0.015
IPX203-B16-02		3	2	44.184	0.001	0.001	1.005	0.005	0.006	0.006	1.015	0.015	0.015
IPX203-B16-02		3	2	1.877	0.000	0.000	1.027	0.027	0.003	0.003	1.044	0.043	0.006
IPX203-B16-02		3	2	30.612	0.004	0.004	0.988	0.012	0.048	0.049	0.978	0.022	0.080
IPX203-B16-02		3	2	3.935	0.001	0.001	1.023	0.023	0.003	0.003	1.037	0.036	0.008
IPX203-B16-02		3	2	38.803	0.005	0.005	0.996	0.004	0.059	0.061	0.977	0.023	0.098
IPX203-B16-02		3	2	8.429	0.001	0.001	1.017	0.016	0.004	0.004	1.024	0.024	0.014
IPX203-B16-02		3	5	3.372	0.000	0.000	1.019	0.018	0.001	0.001	1.017	0.017	0.002
IPX203-B16-02		3	2	14.062	0.002	0.002	1.015	0.015	0.014	0.014	1.016	0.016	0.031
IPX203-B16-02		3	2	10.144	0.001	0.001	1.019	0.019	0.003	0.003	1.029	0.028	0.011
IPX203-B16-02		3	2	1.794	0.000	0.000	1.029	0.029	0.003	0.003	1.044	0.043	0.006
IPX203-B16-02		3	2	3.609	0.001	0.001	1.023	0.023	0.004	0.004	1.036	0.036	0.011
IPX203-B16-02		3	2	18.032	0.000	0.000	1.017	0.017	0.003	0.003	1.033	0.032	0.006
IPX203-B16-02		3	2	3.747	0.000	0.000	1.025	0.024	0.003	0.003	1.040	0.039	0.005
IPX203-B16-02		3	2	8.039	0.001	0.001	1.017	0.017	0.004	0.004	1.028	0.027	0.012
IPX203-B16-02		3	2	15.926	0.000	0.000	1.019	0.019	0.003	0.003	1.035	0.035	0.006
IPX203-B16-02		3	2	18.371	0.002	0.002	1.029	0.028	0.003	0.003	1.031	0.030	0.015
IPX203-B16-02		3	5	1.73	0.000	0.000	1.012	0.011	0.000	0.000	0.988	0.012	0.000
IPX203-B16-02		3	2	5.394	0.000	0.000	1.024	0.023	0.003	0.003	1.041	0.041	0.004
IPX203-B16-02		3	2	2.58	0.000	0.000	1.027	0.027	0.003	0.003	1.045	0.044	0.006
IPX203-B16-02		3	2	1.606	0.001	0.001	1.026	0.026	0.003	0.003	1.042	0.041	0.006
IPX203-B16-02		3	2	4.011	0.001	0.001	1.023	0.022	0.002	0.002	1.038	0.037	0.007
IPX203-B16-02		2	2	11.546	0.001	0.001	1.005	0.005	0.003	0.003	1.009	0.009	0.013
IPX203-B16-02		3	2	3.574	0.001	0.001	1.022	0.022	0.002	0.002	1.037	0.036	0.007
IPX203-B16-02		3	2	5.833	0.001	0.001	1.022	0.022	0.004	0.004	1.032	0.032	0.011
IPX203-B16-02		3	2	23.15	0.003	0.003	1.010	0.010	0.024	0.024	1.007	0.007	0.042
IPX203-B16-02		1	2	3.794	0.001	0.001	1.009	0.009	0.002	0.002	1.011	0.011	0.005
IPX203-B16-02		3	2	14.38	0.001	0.001	1.012	0.012	0.005	0.005	1.021	0.021	0.016
IPX203-B16-02		3	2	12.493	0.001	0.001	1.017	0.017	0.004	0.004	1.025	0.025	0.014

IPX203-B16-02-	(b) (6)	3	2	35.212	0.005	0.005	0.990	0.010	0.053	0.054	0.976	0.023	0.091
IPX203-B16-02-		3	2	24.747	0.001	0.001	1.013	0.013	0.005	0.005	1.023	0.023	0.014
IPX203-B16-02-		3	2	10.739	0.001	0.001	1.017	0.017	0.003	0.003	1.029	0.029	0.010
IPX203-B16-02-		3	2	16.363	0.002	0.002	1.032	0.032	0.015	0.015	1.071	0.070	0.026
IPX203-B16-02-		3	2	148.946	0.008	0.009	0.962	0.038	0.115	0.119	0.910	0.092	0.182
IPX203-B16-02-		3	2	11.046	0.000	0.000	1.019	0.019	0.003	0.003	1.026	0.026	0.006
IPX203-B16-02-		3	2	51.758	0.004	0.004	0.996	0.004	0.036	0.037	0.981	0.019	0.069
IPX203-B16-02-		3	2	40.443	0.006	0.006	1.034	0.034	0.022	0.021	1.062	0.061	0.065
IPX203-B16-02-		3	2	13.476	0.001	0.001	1.022	0.022	0.003	0.003	1.033	0.033	0.006
IPX203-B16-02-		3	5	0.669	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02-		3	2	7.844	0.000	0.000	1.021	0.021	0.003	0.003	1.033	0.033	0.005
IPX203-B16-02-		3	2	54.989	0.005	0.005	0.983	0.017	0.052	0.053	0.944	0.056	0.093
IPX203-B16-02-		3	2	18.448	0.002	0.002	1.036	0.035	0.018	0.018	1.081	0.080	0.030
IPX203-B16-02-		3	2	1.809	0.000	0.000	1.037	0.036	0.004	0.004	1.066	0.064	0.007
IPX203-B16-02-		3	2	9.573	0.002	0.002	1.013	0.013	0.007	0.007	1.016	0.016	0.020
IPX203-B16-02-		2	2	2.362	0.000	0.000	1.027	0.027	0.001	0.001	1.027	0.027	0.004
IPX203-B16-02-		3	2	52.488	0.017	0.017	1.040	0.040	0.065	0.066	1.018	0.020	0.189
IPX203-B16-02-		3	2	13.356	0.002	0.002	1.010	0.010	0.009	0.009	1.012	0.012	0.023
IPX203-B16-02-		3	2	8.163	0.002	0.002	1.012	0.012	0.012	0.012	1.019	0.019	0.029
IPX203-B16-02-		3	2	34.139	0.002	0.002	1.010	0.010	0.007	0.007	1.013	0.013	0.018
IPX203-B16-02-		3	2	39.569	0.003	0.003	1.014	0.014	0.005	0.005	1.014	0.014	0.025
IPX203-B16-02-		3	2	19.651	0.001	0.001	1.015	0.015	0.004	0.004	1.021	0.021	0.013
IPX203-B16-02-		3	2	5.269	0.001	0.001	1.022	0.022	0.003	0.003	1.036	0.036	0.006
IPX203-B16-02-		3	2	29.102	0.006	0.006	1.006	0.006	0.049	0.050	0.990	0.009	0.090
IPX203-B16-02-		3	2	17.083	0.001	0.001	1.025	0.025	0.006	0.006	1.042	0.042	0.014
IPX203-B16-02-		3	2	7.633	0.002	0.002	1.017	0.017	0.009	0.009	1.019	0.019	0.024
IPX203-B16-02-		3	2	4.272	0.001	0.001	1.021	0.021	0.003	0.003	1.033	0.032	0.011
IPX203-B16-02-		3	2	4.807	0.001	0.001	1.022	0.022	0.003	0.003	1.032	0.031	0.010
IPX203-B16-02-		3	2	82.244	0.007	0.007	0.986	0.014	0.132	0.137	0.978	0.020	0.183
IPX203-B16-02-		3	2	8.773	0.002	0.002	1.026	0.025	0.004	0.004	1.028	0.027	0.015
IPX203-B16-02-		3	2	21.128	0.001	0.001	1.023	0.023	0.006	0.006	1.041	0.040	0.013
IPX203-B16-02-		3	2	4.626	0.001	0.001	1.020	0.020	0.003	0.003	1.029	0.028	0.012
IPX203-B16-02-		2	2	19.527	0.002	0.002	1.034	0.034	0.058	0.055	1.094	0.096	0.069
IPX203-B16-02-		3	2	5.761	0.000	0.000	1.026	0.026	0.004	0.004	1.041	0.040	0.005
IPX203-B16-02-		3	2	17.474	0.003	0.003	1.012	0.012	0.020	0.020	1.011	0.011	0.041
IPX203-B16-02-		3	2	5.225	0.001	0.001	1.020	0.020	0.003	0.003	1.031	0.030	0.010
IPX203-B16-02-		3	2	9.374	0.001	0.001	1.020	0.020	0.003	0.003	1.034	0.034	0.007
IPX203-B16-02-		3	2	65.429	0.010	0.010	1.024	0.024	0.067	0.068	1.019	0.020	0.136
IPX203-B16-02-		3	2	5.258	0.001	0.001	1.032	0.031	0.003	0.003	1.039	0.038	0.006
IPX203-B16-02-		3	2	1.757	0.000	0.000	1.026	0.026	0.003	0.003	1.043	0.042	0.005
IPX203-B16-02-		3	2	6.893	0.002	0.002	1.015	0.015	0.007	0.007	1.020	0.020	0.021
IPX203-B16-02-		3	2	15.736	0.002	0.002	1.006	0.006	0.011	0.011	1.008	0.008	0.028
IPX203-B16-02-		1	2	16.035	0.001	0.001	0.993	0.007	0.002	0.002	0.988	0.012	0.009
IPX203-B16-02-		3	2	10.58	0.002	0.002	1.011	0.011	0.010	0.010	1.016	0.016	0.026
IPX203-B16-02-		3	2	8.746	0.001	0.001	1.025	0.024	0.004	0.004	1.034	0.033	0.013
IPX203-B16-02-		3	2	104.67	0.005	0.005	0.974	0.026	0.080	0.083	0.960	0.040	0.117
IPX203-B16-02-		3	2	35.911	0.007	0.007	0.984	0.016	0.119	0.124	0.957	0.043	0.172
IPX203-B16-02-		3	2	4.825	0.001	0.001	1.021	0.021	0.004	0.004	1.033	0.032	0.013
IPX203-B16-02-		1	2	20.93	0.004	0.004	0.994	0.006	0.005	0.005	0.975	0.025	0.033
IPX203-B16-02-		3	2	10.761	0.002	0.002	1.017	0.017	0.010	0.010	1.023	0.023	0.023
IPX203-B16-02-		1	2	1.05	0.000	0.000	1.011	0.011	0.001	0.001	1.018	0.018	0.002
IPX203-B16-02-		3	2	19.419	0.004	0.004	1.012	0.012	0.023	0.023	0.997	0.002	0.048
IPX203-B16-02-		3	2	19.987	0.004	0.004	1.018	0.018	0.021	0.022	1.011	0.011	0.048
IPX203-B16-02-		1	2	10.564	0.001	0.001	0.998	0.003	0.001	0.001	0.999	0.001	0.005
IPX203-B16-02-		3	5	3.216	0.000	0.000	1.020	0.019	0.001	0.001	1.017	0.017	0.002
IPX203-B16-02-		3	2	47.778	0.006	0.006	1.004	0.004	0.027	0.028	0.998	0.002	0.070
IPX203-B16-02-		3	2	31.562	0.001	0.001	1.005	0.005	0.010	0.010	0.995	0.004	0.017
IPX203-B16-02-		3	2	174.6	0.017	0.017	0.942	0.058	0.158	0.168	0.855	0.150	0.290
IPX203-B16-02-		3	2	0.996	0.000	0.000	1.030	0.030	0.003	0.003	1.063	0.061	0.004
IPX203-B16-02-		3	2	22.565	0.001	0.001	1.007	0.007	0.010	0.010	0.999	0.001	0.020
IPX203-B16-02-		3	2	20.299	0.002	0.002	1.011	0.011	0.009	0.009	0.999	0.000	0.025
IPX203-B16-02-		3	2	6.271	0.000	0.000	1.023	0.023	0.004	0.004	1.039	0.039	0.005
IPX203-B16-02-		3	2	3.652	0.001	0.001	1.039	0.038	0.008	0.008	1.078	0.077	0.015
IPX203-B16-02-		3	2	23.047	0.006	0.006	0.987	0.013	0.082	0.085	0.964	0.036	0.128
IPX203-B16-02-		3	2	5.096	0.000	0.000	1.026	0.026	0.003	0.003	1.044	0.043	0.005
IPX203-B16-02-		3	2	33.417	0.003	0.003	1.022	0.022	0.009	0.009	1.036	0.036	0.027
IPX203-B16-02-		3	2	6.97	0.001	0.001	1.024	0.024	0.003	0.003	1.041	0.041	0.010
IPX203-B16-02-		3	2	8.74	0.001	0.001	1.018	0.018	0.004	0.004	1.026	0.026	0.012
IPX203-B16-02-		3	2	6.509	0.001	0.001	1.029	0.029	0.002	0.002	1.035	0.034	0.009
IPX203-B16-02-		3	2	29.294	0.001	0.001	1.017	0.017	0.005	0.005	1.026	0.026	0.013
IPX203-B16-02-		3	2	3.527	0.001	0.001	1.029	0.029	0.003	0.002	1.038	0.038	0.006
IPX203-B16-02-		3	2	4.001	0.001	0.001	1.025	0.025	0.003	0.003	1.042	0.042	0.007
IPX203-B16-02-		3	2	28.596	0.001	0.001	1.018	0.017	0.004	0.004	1.026	0.026	0.013
IPX203-B16-02-		1	2	5.291	0.001	0.001	1.011	0.011	0.000	0.000	1.015	0.015	0.008
IPX203-B16-02-		3	5	1.217	0.000	0.000	1.012	0.012	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02-		2	2	8.027	0.001	0.001	1.016	0.016	0.001	0.001	1.028	0.027	0.005
IPX203-B16-02-		3	2	10.029	0.001	0.001	1.020	0.019	0.003	0.003	1.030	0.029	0.011
IPX203-B16-02-		2	2	33.843	0.002	0.002	0.991	0.009	0.010	0.010	0.962	0.038	0.024
IPX203-B16-02-		3	2	12.996	0.004	0.004	1.011	0.011	0.036	0.037	1.024	0.025	0.066
IPX203-B16-02-		1	2	30.784	0.003	0.003	0.977	0.023	0.017	0.017	0.926	0.076	0.040
IPX203-B16-02-		3	2	6.145	0.001	0.001	1.035	0.035	0.008	0.008	1.083	0.082	0.013
IPX203-B16-02-		3	2	5.165	0.000	0.000	1.024	0.024	0.003	0.003	1.040	0.040	0.006
IPX203-B16-02-		1	2	12.884	0.002	0.002	1.007	0.007	0.003	0.003	1.007	0.007	0.019
IPX203-B16-02-		3	5	1.73	0.000	0.000	1.017	0.017	0.000	0.000	0.987	0.013	0.002


IPX203-B16-02	(b) (6)	1	2	3.609	0.000	0.000	1.005	0.005	0.001	0.001	1.010	0.010	0.003
IPX203-B16-02		3	5	3.602	0.000	0.000	1.019	0.019	0.001	0.001	1.016	0.016	0.002
IPX203-B16-02		3	5	2.716	0.000	0.000	1.019	0.019	0.001	0.001	1.016	0.016	0.001
IPX203-B16-02		1	2	3.957	0.000	0.000	1.006	0.006	0.001	0.001	1.008	0.008	0.003
IPX203-B16-02		3	2	19.677	0.005	0.005	0.992	0.008	0.052	0.054	0.971	0.029	0.088
IPX203-B16-02		2	2	18.265	0.002	0.002	1.019	0.019	0.008	0.008	1.032	0.032	0.020
IPX203-B16-02		1	2	3.56	0.001	0.001	1.012	0.012	0.001	0.001	1.023	0.023	0.005
IPX203-B16-02		3	2	70.868	0.003	0.003	0.997	0.003	0.022	0.022	0.992	0.008	0.041
IPX203-B16-02		3	2	4.764	0.001	0.001	1.024	0.024	0.003	0.003	1.041	0.040	0.008
IPX203-B16-02		3	2	13.323	0.004	0.004	1.008	0.008	0.029	0.029	0.993	0.007	0.056
IPX203-B16-02		3	2	30.576	0.006	0.006	0.988	0.011	0.081	0.083	0.967	0.032	0.125
IPX203-B16-02		3	2	4.447	0.001	0.001	1.030	0.030	0.004	0.004	1.059	0.058	0.009
IPX203-B16-02		3	2	1.342	0.000	0.000	1.034	0.034	0.003	0.003	1.055	0.053	0.005
IPX203-B16-02		1	2	50.225	0.005	0.005	0.966	0.035	0.051	0.052	0.900	0.104	0.088
IPX203-B16-02		3	2	4.961	0.001	0.001	1.030	0.030	0.004	0.004	1.058	0.057	0.008
IPX203-B16-02		2	2	11.979	0.001	0.001	1.019	0.019	0.008	0.008	1.041	0.041	0.016
IPX203-B16-02		2	2	44.846	0.006	0.006	1.016	0.016	0.074	0.072	1.033	0.036	0.113
IPX203-B16-02		3	2	206.107	0.011	0.012	0.917	0.084	0.481	0.525	0.851	0.155	0.593
IPX203-B16-02		3	2	210.234	0.017	0.018	0.916	0.085	0.616	0.678	0.841	0.166	0.771
IPX203-B16-02		3	2	43.926	0.003	0.003	1.029	0.029	0.046	0.046	1.070	0.070	0.065
IPX203-B16-02		3	2	12.988	0.003	0.003	1.020	0.020	0.015	0.015	1.022	0.022	0.036
IPX203-B16-02		3	2	3.724	0.000	0.000	1.024	0.024	0.003	0.003	1.039	0.039	0.005
IPX203-B16-02		3	2	24.057	0.002	0.002	1.007	0.008	0.009	0.009	1.004	0.004	0.023
IPX203-B16-02		2	2	6.076	0.001	0.001	1.015	0.015	0.001	0.001	1.029	0.028	0.006
IPX203-B16-02		3	2	2.046	0.001	0.001	1.032	0.031	0.002	0.002	1.042	0.041	0.006
IPX203-B16-02		3	2	31.338	0.002	0.002	1.012	0.012	0.013	0.013	1.018	0.018	0.031
IPX203-B16-02		3	2	36.7	0.002	0.002	1.019	0.019	0.011	0.011	1.038	0.038	0.023
IPX203-B16-02		3	2	56.063	0.003	0.003	1.011	0.011	0.026	0.027	1.022	0.022	0.048
IPX203-B16-02		3	5	1.429	0.000	0.000	1.017	0.017	0.000	0.000	1.002	0.002	0.002
IPX203-B16-02		3	2	10.694	0.002	0.002	1.034	0.033	0.003	0.003	1.046	0.045	0.014
IPX203-B16-02		3	2	12.584	0.002	0.002	1.015	0.015	0.008	0.008	1.025	0.025	0.021
IPX203-B16-02		3	2	7.208	0.001	0.001	1.022	0.021	0.003	0.003	1.033	0.032	0.010
IPX203-B16-02		3	2	9.607	0.001	0.001	1.025	0.025	0.003	0.003	1.039	0.038	0.007
IPX203-B16-02		3	2	9.09	0.001	0.001	1.025	0.025	0.003	0.003	1.039	0.039	0.007
IPX203-B16-02		3	2	26.031	0.003	0.003	1.002	0.002	0.025	0.026	0.991	0.009	0.051
IPX203-B16-02		3	2	11.08	0.002	0.002	1.027	0.026	0.011	0.011	1.061	0.060	0.022
IPX203-B16-02		3	2	3.848	0.000	0.000	1.025	0.025	0.003	0.003	1.041	0.040	0.004
IPX203-B16-02		3	2	20.179	0.002	0.002	1.009	0.009	0.008	0.008	1.004	0.004	0.022
IPX203-B16-02		3	2	1.714	0.000	0.000	1.026	0.025	0.003	0.003	1.042	0.041	0.005
IPX203-B16-02		1	2	0.812	0.000	0.000	1.009	0.009	0.001	0.001	1.019	0.019	0.001
IPX203-B16-02		3	2	14.104	0.003	0.003	1.012	0.012	0.013	0.013	1.015	0.015	0.030
IPX203-B16-02		1	2	0.497	0.000	0.000	1.012	0.012	0.001	0.001	1.020	0.020	0.002
IPX203-B16-02		3	2	7.438	0.000	0.000	1.025	0.025	0.003	0.003	1.042	0.041	0.006
IPX203-B16-02		3	2	8.941	0.001	0.001	1.030	0.030	0.003	0.003	1.042	0.041	0.009
IPX203-B16-02		3	2	11.85	0.001	0.001	1.016	0.016	0.004	0.004	1.022	0.022	0.014
IPX203-B16-02		3	2	6.366	0.001	0.001	1.024	0.024	0.002	0.002	1.038	0.037	0.006
IPX203-B16-02		3	5	2.4	0.000	0.000	1.012	0.012	0.000	0.000	0.989	0.011	0.001
IPX203-B16-02		3	5	3.967	0.000	0.000	1.027	0.027	0.001	0.001	1.016	0.016	0.004
IPX203-B16-02		2	2	0.686	0.000	0.000	1.018	0.018	0.002	0.002	1.033	0.032	0.003
IPX203-B16-02		3	2	60.596	0.003	0.003	1.000	0.000	0.035	0.036	0.997	0.003	0.059
IPX203-B16-02		3	2	11.618	0.002	0.002	1.026	0.026	0.004	0.004	1.037	0.037	0.014
IPX203-B16-02		3	5	3.05	0.000	0.000	1.013	0.013	0.000	0.000	0.984	0.016	0.001
IPX203-B16-02		2	2	11.9	0.002	0.002	1.014	0.014	0.005	0.005	1.017	0.017	0.017
IPX203-B16-02		3	2	1.442	0.000	0.000	1.025	0.024	0.003	0.003	1.041	0.040	0.005
IPX203-B16-02		3	2	18.894	0.002	0.002	1.020	0.019	0.008	0.008	1.032	0.032	0.021
IPX203-B16-02		3	2	6.147	0.002	0.002	1.021	0.021	0.005	0.005	1.024	0.024	0.015
IPX203-B16-02		3	2	4.329	0.001	0.001	1.032	0.032	0.004	0.004	1.061	0.060	0.009
IPX203-B16-02		3	2	28.319	0.001	0.001	1.015	0.015	0.003	0.003	1.012	0.012	0.012
IPX203-B16-02		3	5	0.957	0.000	0.000	1.015	0.015	0.000	0.000	0.989	0.012	0.001
IPX203-B16-02		3	2	12.638	0.001	0.001	1.016	0.016	0.004	0.004	1.018	0.018	0.012
IPX203-B16-02		3	5	2.586	0.000	0.000	1.022	0.022	0.001	0.001	1.016	0.016	0.003
IPX203-B16-02		3	2	28.185	0.002	0.002	1.011	0.011	0.008	0.008	1.004	0.004	0.024
IPX203-B16-02		3	2	10.286	0.001	0.001	1.021	0.021	0.003	0.003	1.028	0.028	0.007
IPX203-B16-02		3	2	9.068	0.001	0.001	1.017	0.017	0.004	0.004	1.023	0.022	0.012
IPX203-B16-02		3	2	8.151	0.001	0.001	1.029	0.029	0.007	0.006	1.060	0.059	0.015
IPX203-B16-02		3	2	49.778	0.010	0.011	0.957	0.043	0.277	0.296	0.902	0.100	0.367
IPX203-B16-02		3	2	7.184	0.002	0.002	1.037	0.036	0.010	0.009	1.072	0.071	0.020
IPX203-B16-02		3	2	13.964	0.001	0.001	1.019	0.019	0.004	0.004	1.023	0.023	0.008
IPX203-B16-02		3	2	5.342	0.001	0.001	1.023	0.023	0.003	0.003	1.042	0.042	0.011
IPX203-B16-02		3	2	4.942	0.001	0.001	1.028	0.028	0.003	0.003	1.055	0.054	0.009
IPX203-B16-02		3	2	14.711	0.003	0.003	1.019	0.019	0.016	0.016	1.035	0.035	0.034
IPX203-B16-02		3	2	33.776	0.001	0.001	1.008	0.008	0.008	0.009	1.000	0.001	0.018
IPX203-B16-02		3	2	69.445	0.006	0.006	0.996	0.004	0.020	0.020	0.967	0.033	0.063
IPX203-B16-02		3	2	45.704	0.008	0.008	0.979	0.021	0.126	0.131	0.932	0.068	0.187
IPX203-B16-02		2	2	20.431	0.007	0.007	1.028	0.029	0.023	0.024	0.986	0.014	0.073
IPX203-B16-02		3	5	0.224	0.000	0.000	1.014	0.014	0.000	0.000	0.986	0.014	0.000
IPX203-B16-02		3	2	8.707	0.001	0.001	1.021	0.021	0.003	0.003	1.030	0.029	0.006
IPX203-B16-02		3	2	10.199	0.000	0.000	1.021	0.020	0.003	0.003	1.029	0.029	0.006
IPX203-B16-02		3	2	20.017	0.001	0.001	1.017	0.017	0.004	0.004	1.020	0.020	0.009
IPX203-B16-02		3	2	10.501	0.002	0.002	1.021	0.021	0.010	0.010	1.045	0.044	0.023
IPX203-B16-02		3	2	18.805	0.001	0.001	1.016	0.016	0.004	0.004	1.020	0.020	0.009
IPX203-B16-02		3	2	5.505	0.001	0.001	1.022	0.022	0.003	0.003	1.036	0.036	0.012
IPX203-B16-02		3	2	6.013	0.000	0.000	1.027	0.027	0.003	0.003	1.035	0.034	0.006
IPX203-B16-02		3	2	3.088	0.001	0.001	1.024	0.024	0.002	0.002	1.037	0.037	0.008

IPX203-B16-02	(b) (6)	3	2	36.526	0.002	0.002	1.013	0.013	0.005	0.005	1.012	0.012	0.020
IPX203-B16-02		3	2	28.188	0.007	0.007	0.992	0.008	0.105	0.108	0.990	0.008	0.153
IPX203-B16-02		3	2	40.106	0.003	0.003	1.018	0.018	0.006	0.006	1.015	0.015	0.030
IPX203-B16-02		3	2	8.569	0.001	0.001	1.029	0.029	0.004	0.004	1.050	0.049	0.011
IPX203-B16-02		3	2	13.899	0.003	0.003	1.006	0.006	0.025	0.025	1.004	0.005	0.049
IPX203-B16-02		3	5	0.341	0.000	0.000	1.013	0.013	0.000	0.000	0.985	0.015	0.001
IPX203-B16-02		3	2	38.414	0.002	0.002	1.005	0.005	0.009	0.009	1.004	0.004	0.024
IPX203-B16-02		3	2	25.295	0.003	0.003	1.032	0.031	0.010	0.009	1.047	0.047	0.032
IPX203-B16-02		3	2	25.511	0.003	0.003	1.006	0.006	0.019	0.020	1.002	0.002	0.041
IPX203-B16-02		3	2	27.392	0.003	0.003	1.020	0.020	0.019	0.019	1.036	0.037	0.038
IPX203-B16-02		3	2	13.475	0.001	0.001	1.030	0.030	0.005	0.005	1.049	0.049	0.012
IPX203-B16-02		3	2	2.59	0.000	0.000	1.025	0.025	0.003	0.003	1.041	0.040	0.005
IPX203-B16-02		3	2	12.288	0.001	0.001	1.018	0.018	0.003	0.003	1.027	0.027	0.009
IPX203-B16-02		3	2	19.511	0.001	0.001	1.021	0.021	0.003	0.003	1.026	0.026	0.012
IPX203-B16-02		3	2	12.052	0.003	0.003	1.008	0.008	0.015	0.015	1.009	0.009	0.033
IPX203-B16-02		3	2	26.144	0.006	0.006	0.982	0.018	0.091	0.095	0.954	0.046	0.139
IPX203-B16-02		3	2	42.489	0.008	0.008	0.992	0.008	0.067	0.068	0.954	0.047	0.121
IPX203-B16-02		3	2	6.149	0.001	0.001	1.025	0.024	0.004	0.004	1.043	0.043	0.013
IPX203-B16-02		3	2	42.844	0.006	0.006	1.019	0.019	0.010	0.010	1.012	0.012	0.053
IPX203-B16-02		3	2	25.987	0.003	0.003	1.018	0.018	0.025	0.025	1.041	0.042	0.046
IPX203-B16-02		2	2	23.532	0.004	0.004	1.004	0.004	0.009	0.009	0.982	0.018	0.035
IPX203-B16-02		3	2	6.033	0.001	0.001	1.035	0.035	0.004	0.004	1.059	0.057	0.010
IPX203-B16-02		3	2	8.787	0.002	0.002	1.015	0.015	0.007	0.007	1.021	0.021	0.020
IPX203-B16-02		3	2	12.479	0.003	0.003	1.011	0.011	0.015	0.016	1.010	0.011	0.034
IPX203-B16-02		3	2	2.418	0.001	0.001	1.022	0.022	0.002	0.002	1.036	0.035	0.007
IPX203-B16-02		3	2	13.22	0.002	0.002	1.009	0.009	0.010	0.010	1.013	0.014	0.024
IPX203-B16-02		3	5	1.274	0.000	0.000	1.012	0.012	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02		3	2	5.807	0.000	0.000	1.022	0.022	0.003	0.003	1.036	0.036	0.006
IPX203-B16-02		3	2	13.307	0.002	0.002	1.015	0.015	0.005	0.005	1.020	0.020	0.015
IPX203-B16-02		3	2	4.74	0.001	0.001	1.019	0.019	0.004	0.004	1.026	0.026	0.012
IPX203-B16-02		3	2	10.141	0.002	0.002	1.015	0.015	0.005	0.005	1.021	0.021	0.017
IPX203-B16-02		3	2	3.179	0.001	0.000	1.025	0.025	0.003	0.003	1.039	0.038	0.006
IPX203-B16-02		3	2	4.328	0.001	0.001	1.022	0.022	0.003	0.003	1.038	0.037	0.006
IPX203-B16-02		3	2	3.189	0.001	0.001	1.023	0.023	0.003	0.003	1.037	0.036	0.006
IPX203-B16-02		3	5	0.627	0.000	0.000	1.012	0.012	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	7.254	0.000	0.000	1.023	0.022	0.003	0.003	1.038	0.037	0.005
IPX203-B16-02		3	2	18.152	0.001	0.001	1.017	0.017	0.004	0.004	1.026	0.026	0.014
IPX203-B16-02		3	2	11.751	0.001	0.001	1.015	0.015	0.004	0.004	1.033	0.033	0.012
IPX203-B16-02		3	2	8.183	0.002	0.002	1.039	0.038	0.017	0.017	1.062	0.061	0.028
IPX203-B16-02		3	2	23.378	0.003	0.003	1.006	0.007	0.023	0.024	0.999	0.000	0.047
IPX203-B16-02		3	2	68.892	0.013	0.013	0.974	0.026	0.192	0.201	0.927	0.073	0.286
IPX203-B16-02		3	2	89.205	0.004	0.004	0.984	0.016	0.025	0.026	0.978	0.022	0.056
IPX203-B16-02		3	2	35.9	0.001	0.001	1.008	0.008	0.010	0.010	1.019	0.019	0.017
IPX203-B16-02		3	2	0.85	0.000	0.000	1.030	0.030	0.004	0.004	1.057	0.056	0.005
IPX203-B16-02		3	2	32.475	0.001	0.001	1.008	0.008	0.008	0.008	1.020	0.020	0.013
IPX203-B16-02		3	2	24.668	0.001	0.001	1.015	0.015	0.006	0.006	1.028	0.027	0.012
IPX203-B16-02		3	2	46.778	0.002	0.002	0.997	0.003	0.014	0.015	1.002	0.002	0.028
IPX203-B16-02		3	2	95.736	0.007	0.008	0.958	0.042	0.143	0.150	0.923	0.078	0.205
IPX203-B16-02		3	2	6.107	0.001	0.001	1.035	0.034	0.015	0.015	1.058	0.058	0.024
IPX203-B16-02		3	5	1.898	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	13.6	0.001	0.001	1.015	0.015	0.004	0.004	1.028	0.028	0.014
IPX203-B16-02		3	2	13.6	0.001	0.001	1.015	0.015	0.004	0.004	1.028	0.028	0.014
IPX203-B16-02		3	2	1.735	0.000	0.000	1.032	0.031	0.003	0.003	1.055	0.054	0.006
IPX203-B16-02		3	2	34.525	0.004	0.004	0.997	0.003	0.028	0.028	0.988	0.012	0.054
IPX203-B16-02		3	2	11.522	0.002	0.002	1.026	0.025	0.017	0.016	1.040	0.039	0.029
IPX203-B16-02		3	2	7.282	0.001	0.001	1.024	0.024	0.003	0.003	1.039	0.038	0.010
IPX203-B16-02		3	2	1.684	0.000	0.000	1.028	0.028	0.003	0.003	1.054	0.053	0.005
IPX203-B16-02		3	2	34.825	0.001	0.001	1.005	0.005	0.009	0.009	1.018	0.018	0.015
IPX203-B16-02		3	2	14.888	0.001	0.001	1.017	0.017	0.004	0.004	1.033	0.033	0.008
IPX203-B16-02		3	2	23.159	0.005	0.005	1.002	0.003	0.062	0.063	0.995	0.004	0.096
IPX203-B16-02		3	2	3.361	0.001	0.001	1.028	0.028	0.003	0.003	1.041	0.040	0.009
IPX203-B16-02		3	2	20.885	0.004	0.004	1.004	0.004	0.024	0.024	0.987	0.013	0.052
IPX203-B16-02		3	2	8.532	0.001	0.001	1.024	0.024	0.003	0.003	1.032	0.032	0.007
IPX203-B16-02		3	2	25.727	0.002	0.002	1.013	0.013	0.004	0.004	1.008	0.008	0.019
IPX203-B16-02		3	2	30.338	0.005	0.005	1.006	0.006	0.055	0.056	1.001	0.002	0.093
IPX203-B16-02		3	2	14.748	0.000	0.000	1.019	0.019	0.003	0.003	1.026	0.026	0.006
IPX203-B16-02		3	2	2.876	0.000	0.000	1.030	0.030	0.003	0.003	1.056	0.054	0.005
IPX203-B16-02		3	2	5.262	0.001	0.001	1.018	0.018	0.004	0.004	1.024	0.024	0.013
IPX203-B16-02		3	2	1.422	0.000	0.000	1.030	0.030	0.003	0.003	1.056	0.055	0.004
IPX203-B16-02		3	2	4.372	0.001	0.001	1.022	0.022	0.003	0.003	1.031	0.031	0.010
IPX203-B16-02		1	2	0.029	0.000	0.000	1.010	0.010	0.001	0.001	1.023	0.023	0.001
IPX203-B16-02		3	2	46.233	0.003	0.003	1.009	0.009	0.022	0.022	1.018	0.018	0.043
IPX203-B16-02		3	2	19.636	0.004	0.004	1.005	0.005	0.028	0.029	0.994	0.006	0.055
IPX203-B16-02		3	2	3.735	0.000	0.000	1.027	0.026	0.003	0.003	1.048	0.047	0.005
IPX203-B16-02		3	2	10.588	0.001	0.001	1.023	0.022	0.003	0.002	1.036	0.036	0.007
IPX203-B16-02		3	2	19.693	0.002	0.002	1.026	0.025	0.003	0.003	1.030	0.030	0.016
IPX203-B16-02		3	2	39.444	0.008	0.008	0.974	0.026	0.150	0.157	0.945	0.055	0.210
IPX203-B16-02		3	2	13.853	0.001	0.001	1.023	0.022	0.003	0.003	1.039	0.038	0.008
IPX203-B16-02		3	5	3.029	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.014	0.001
IPX203-B16-02		3	5	0.879	0.000	0.000	1.012	0.012	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	14.039	0.003	0.003	1.003	0.003	0.023	0.024	0.996	0.004	0.048
IPX203-B16-02		3	2	8.248	0.000	0.000	1.025	0.024	0.002	0.002	1.040	0.039	0.005
IPX203-B16-02		3	2	37.828	0.002	0.002	1.017	0.017	0.009	0.009	1.021	0.021	0.025
IPX203-B16-02		3	5	1.414	0.000	0.000	1.018	0.018	0.000	0.000	0.988	0.012	0.002

IPX203-B16-02	(b) (6)	3	2	34.241	0.006	0.006	0.987	0.013	0.075	0.078	0.961	0.039	0.120
IPX203-B16-02		3	2	16.623	0.004	0.004	1.005	0.005	0.027	0.027	0.998	0.002	0.052
IPX203-B16-02		3	2	3.316	0.000	0.000	1.024	0.024	0.003	0.003	1.039	0.038	0.005
IPX203-B16-02		3	2	7.915	0.001	0.001	1.028	0.028	0.003	0.003	1.037	0.037	0.007
IPX203-B16-02		3	2	30.841	0.005	0.005	1.008	0.009	0.034	0.035	0.990	0.010	0.072
IPX203-B16-02		1	2	7.976	0.001	0.001	1.005	0.005	0.000	0.000	1.005	0.005	0.006
IPX203-B16-02		3	2	13.196	0.003	0.003	1.009	0.009	0.014	0.014	1.012	0.012	0.032
IPX203-B16-02		3	2	60.527	0.004	0.004	1.011	0.011	0.021	0.021	1.010	0.010	0.047
IPX203-B16-02		3	2	21.606	0.004	0.004	1.012	0.012	0.023	0.024	1.000	0.000	0.051




***Note:** Four highlighted individuals showed the high influence on the fitted model, hence, the change from baseline to Visit7/ET in “Good on” Time during the double-blind treatment period were displayed below. The same MMRM analyses were performed after excluding each high influential individual at a time to check these individuals leaning any change in the overall result.




IPX203 vs. IR CD-LD			
USUBJID EXCLUDED in the model		LS Mean Difference (95% CI)	p-value
IPX203-B16-02-	(b) (6)	0.5391 (0.0964, 0.9819)	0.0170
IPX203-B16-02-	(b) (6)	0.5719 (0.1367, 1.0070)	0.0100
IPX203-B16-02-	(b) (6)	0.5345 (0.0913, 0.9778)	0.0181
IPX203-B16-02-	(b) (6)	0.5570 (0.1171, 0.9968)	0.0131

2. Model Diagnostics of Efficacy Analysis (Mixed Model for Repeated Measures) on the primary endpoint (Change in “Off” Time)

2.1 Residual analysis: To check stability of variance and normal distribution of residuals



Tests for Normality				
Test	Statistic		p Value	
Shapiro-Wilk	W	0.975939	Pr < W	<0.0001
Kolmogorov-Smirnov	D	0.061403	Pr > D	<0.0100
Cramer-von Mises	W-Sq	1.594904	Pr > W-Sq	<0.0050
Anderson-Darling	A-Sq	9.488136	Pr > A-Sq	<0.0050



***Note:** The data is not normally distributed, hence, the reviewer performed non-parametric analysis (Wilcoxon rank sum test) for sensitivity analysis.

2.2 Influence analysis: To check stability of the model when a particular data point is removed.

Influence Diagnostics for Levels of USUBJID												
Unique Subject Identifier	Number of Observations in Level	Iterations	PRESS Statistic	Cook's D	MDFFITs	COVRATIO	COVTRACE	Cook's D CovParms	MDFFITs CovParms	COVRATIO CovParms	COVTRACE CovParms	Restricted Likelihood Distance
IPX203-B16-02-(b) (6)	3	5	1.504	0.000	0.000	1.015	0.015	0.000	0.000	0.986	0.015	0.001
IPX203-B16-02-	3	2	8.032	0.001	0.001	1.025	0.025	0.002	0.002	1.035	0.034	0.007
IPX203-B16-02-	1	2	0.879	0.000	0.000	1.012	0.012	0.001	0.001	1.015	0.015	0.002
IPX203-B16-02-	3	2	30.664	0.002	0.002	1.008	0.008	0.016	0.016	1.008	0.008	0.032
IPX203-B16-02-	3	2	43.798	0.003	0.003	1.010	0.010	0.029	0.030	1.025	0.025	0.054
IPX203-B16-02-	3	5	1.155	0.000	0.000	1.012	0.012	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-	3	2	41.318	0.003	0.003	1.008	0.008	0.030	0.030	1.022	0.023	0.051
IPX203-B16-02-	3	5	2.755	0.000	0.000	1.019	0.019	0.000	0.000	1.000	0.000	0.002
IPX203-B16-02-	3	2	14.659	0.002	0.002	1.016	0.016	0.005	0.005	1.019	0.019	0.015
IPX203-B16-02-	3	5	1.985	0.000	0.000	1.012	0.012	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02-	3	2	10.593	0.001	0.001	1.026	0.026	0.002	0.002	1.026	0.025	0.011
IPX203-B16-02-	3	2	3.106	0.001	0.001	1.027	0.027	0.002	0.002	1.036	0.035	0.008
IPX203-B16-02-	3	2	27.463	0.005	0.005	0.984	0.016	0.067	0.069	0.957	0.044	0.107
IPX203-B16-02-	3	2	5.369	0.002	0.002	1.018	0.018	0.005	0.005	1.025	0.025	0.018
IPX203-B16-02-	3	2	3.697	0.000	0.000	1.023	0.023	0.003	0.003	1.034	0.034	0.005
IPX203-B16-02-	3	2	37.776	0.002	0.002	1.001	0.001	0.017	0.017	0.992	0.007	0.033
IPX203-B16-02-	1	2	0.041	0.000	0.000	1.016	0.016	0.001	0.001	1.023	0.023	0.001
IPX203-B16-02-	1	2	30.454	0.004	0.004	0.978	0.023	0.015	0.015	0.929	0.073	0.043
IPX203-B16-02-	3	2	27.927	0.004	0.004	1.012	0.012	0.033	0.033	1.023	0.024	0.057
IPX203-B16-02-	3	2	10.464	0.001	0.001	1.032	0.032	0.007	0.007	1.055	0.054	0.015
IPX203-B16-02-	3	2	5.549	0.001	0.001	1.029	0.029	0.005	0.005	1.052	0.051	0.009
IPX203-B16-02-	1	2	0.732	0.000	0.000	1.013	0.013	0.001	0.001	1.023	0.023	0.003
IPX203-B16-02-	1	2	33.578	0.004	0.004	0.974	0.026	0.017	0.017	0.925	0.078	0.043
IPX203-B16-02-	3	2	6.965	0.001	0.001	1.019	0.019	0.003	0.003	1.026	0.026	0.008
IPX203-B16-02-	3	2	15.112	0.002	0.002	1.026	0.026	0.003	0.003	1.040	0.040	0.015
IPX203-B16-02-	3	2	2.903	0.001	0.001	1.024	0.024	0.002	0.002	1.035	0.035	0.007
IPX203-B16-02-	3	2	16.050	0.002	0.002	1.018	0.018	0.006	0.006	1.027	0.027	0.017
IPX203-B16-02-	3	2	10.699	0.000	0.000	1.017	0.017	0.005	0.005	1.020	0.020	0.008
IPX203-B16-02-	3	2	18.171	0.000	0.000	1.011	0.011	0.010	0.010	0.996	0.003	0.014
IPX203-B16-02-	3	2	3.149	0.001	0.001	1.028	0.028	0.003	0.003	1.065	0.064	0.009
IPX203-B16-02-	3	2	46.559	0.002	0.002	0.985	0.014	0.031	0.032	0.933	0.066	0.048
IPX203-B16-02-	3	2	7.341	0.000	0.000	1.021	0.021	0.005	0.005	1.031	0.031	0.006
IPX203-B16-02-	3	2	67.081	0.002	0.002	0.979	0.020	0.036	0.039	0.911	0.087	0.053
IPX203-B16-02-	3	2	11.737	0.001	0.001	1.016	0.016	0.005	0.005	1.015	0.015	0.010
IPX203-B16-02-	3	2	5.646	0.000	0.000	1.027	0.027	0.003	0.003	1.030	0.030	0.006
IPX203-B16-02-	3	2	88.870	0.020	0.021	0.902	0.099	0.804	0.906	0.794	0.220	1.017
IPX203-B16-02-	3	2	18.092	0.002	0.002	1.010	0.010	0.011	0.011	1.006	0.006	0.025
IPX203-B16-02-	3	2	14.579	0.003	0.003	1.005	0.005	0.025	0.025	1.003	0.003	0.049
IPX203-B16-02-	3	2	5.294	0.001	0.001	1.025	0.025	0.003	0.003	1.026	0.025	0.010
IPX203-B16-02-	1	2	0.085	0.000	0.000	1.011	0.011	0.001	0.001	1.020	0.020	0.001
IPX203-B16-02-	3	2	6.250	0.000	0.000	1.032	0.031	0.005	0.005	1.069	0.068	0.008
IPX203-B16-02-	3	2	6.213	0.000	0.000	1.027	0.027	0.003	0.003	1.044	0.043	0.005
IPX203-B16-02-	3	5	1.800	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02-	2	2	5.918	0.002	0.002	1.008	0.008	0.003	0.003	1.007	0.007	0.014
IPX203-B16-02-	3	2	11.721	0.001	0.001	1.020	0.020	0.004	0.004	1.031	0.031	0.014
IPX203-B16-02-	1	2	0.959	0.000	0.000	1.012	0.011	0.001	0.001	1.018	0.018	0.002
IPX203-B16-02-	3	2	23.957	0.002	0.002	1.010	0.010	0.009	0.009	0.999	0.001	0.025
IPX203-B16-02-	3	2	2.169	0.000	0.000	1.031	0.031	0.003	0.003	1.061	0.059	0.005
IPX203-B16-02-	3	2	1.737	0.000	0.000	1.026	0.026	0.002	0.002	1.039	0.038	0.005
IPX203-B16-02-	3	2	4.941	0.000	0.000	1.025	0.025	0.003	0.003	1.033	0.033	0.005
IPX203-B16-02-	1	2	0.742	0.000	0.000	1.008	0.008	0.001	0.001	1.014	0.014	0.001
IPX203-B16-02-	3	2	3.593	0.001	0.001	1.029	0.029	0.003	0.003	1.040	0.039	0.009
IPX203-B16-02-	3	2	12.842	0.002	0.002	1.018	0.018	0.005	0.005	1.033	0.033	0.016
IPX203-B16-02-	3	2	11.722	0.001	0.001	1.018	0.018	0.003	0.002	1.020	0.020	0.010
IPX203-B16-02-	3	2	19.716	0.001	0.001	1.018	0.018	0.004	0.003	1.020	0.020	0.010
IPX203-B16-02-	3	5	0.797	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02-	2	2	1.725	0.000	0.000	1.020	0.019	0.002	0.002	1.026	0.026	0.003
IPX203-B16-02-	3	2	3.659	0.000	0.000	1.026	0.026	0.002	0.002	1.035	0.034	0.005
IPX203-B16-02-	3	2	36.247	0.010	0.011	0.954	0.046	0.275	0.294	0.904	0.097	0.364
IPX203-B16-02-	3	2	12.630	0.003	0.003	1.008	0.008	0.014	0.014	1.003	0.003	0.033
IPX203-B16-02-	3	2	2.681	0.001	0.001	1.026	0.025	0.003	0.003	1.056	0.055	0.009
IPX203-B16-02-	3	2	5.703	0.001	0.001	1.019	0.019	0.003	0.003	1.025	0.024	0.008
IPX203-B16-02-	3	2	11.145	0.001	0.001	1.017	0.017	0.006	0.006	1.011	0.011	0.009
IPX203-B16-02-	3	2	83.523	0.005	0.005	0.971	0.029	0.061	0.064	0.907	0.094	0.094
IPX203-B16-02-	3	5	0.766	0.000	0.000	1.018	0.018	0.000	0.000	0.984	0.016	0.001
IPX203-B16-02-	3	2	13.679	0.001	0.001	1.027	0.026	0.002	0.002	1.037	0.036	0.010
IPX203-B16-02-	3	2	13.881	0.002	0.002	1.020	0.020	0.006	0.006	1.035	0.035	0.019
IPX203-B16-02-	3	2	2.343	0.001	0.001	1.027	0.027	0.003	0.003	1.050	0.049	0.008
IPX203-B16-02-	3	2	7.353	0.001	0.001	1.019	0.019	0.003	0.003	1.020	0.020	0.009
IPX203-B16-02-	3	2	32.661	0.005	0.005	1.019	0.019	0.007	0.007	0.985	0.014	0.041

IPX203-B16-02	(b) (6)	3	2	10.309	0.002	0.002	1.014	0.014	0.005	0.005	1.014	0.014	0.017
IPX203-B16-02		2	2	8.817	0.001	0.001	1.015	0.015	0.003	0.003	1.000	0.000	0.010
IPX203-B16-02		3	2	25.411	0.001	0.001	1.010	0.010	0.006	0.006	0.993	0.006	0.014
IPX203-B16-02		3	2	7.260	0.001	0.001	1.032	0.031	0.007	0.007	1.076	0.075	0.013
IPX203-B16-02		3	2	42.180	0.002	0.002	1.001	0.001	0.010	0.010	0.988	0.012	0.024
IPX203-B16-02		3	2	44.294	0.003	0.003	1.008	0.008	0.007	0.007	0.997	0.003	0.029
IPX203-B16-02		3	2	31.375	0.004	0.005	1.002	0.002	0.056	0.057	1.002	0.003	0.090
IPX203-B16-02		3	2	5.725	0.001	0.001	1.023	0.023	0.004	0.004	1.039	0.038	0.014
IPX203-B16-02		3	2	9.028	0.001	0.001	1.014	0.014	0.005	0.005	1.015	0.015	0.015
IPX203-B16-02		3	2	17.561	0.003	0.003	1.001	0.001	0.024	0.024	0.988	0.012	0.048
IPX203-B16-02		3	2	18.430	0.001	0.001	1.019	0.019	0.003	0.003	1.016	0.016	0.011
IPX203-B16-02		3	2	4.403	0.001	0.001	1.020	0.020	0.003	0.003	1.030	0.029	0.010
IPX203-B16-02		3	2	3.817	0.000	0.000	1.026	0.026	0.003	0.003	1.047	0.046	0.006
IPX203-B16-02		3	5	1.675	0.000	0.000	1.016	0.016	0.000	0.000	0.989	0.011	0.001
IPX203-B16-02		3	2	15.987	0.004	0.004	1.007	0.008	0.033	0.034	0.998	0.001	0.062
IPX203-B16-02		3	2	12.459	0.003	0.003	1.014	0.014	0.019	0.019	1.025	0.025	0.039
IPX203-B16-02		3	2	12.303	0.001	0.001	1.017	0.017	0.003	0.003	1.021	0.021	0.008
IPX203-B16-02		3	5	3.437	0.000	0.000	1.020	0.020	0.001	0.001	1.013	0.013	0.002
IPX203-B16-02		1	2	6.446	0.000	0.000	0.999	0.001	0.002	0.002	0.981	0.019	0.005
IPX203-B16-02		3	2	12.437	0.001	0.001	1.014	0.014	0.005	0.005	1.008	0.008	0.013
IPX203-B16-02		3	2	10.582	0.001	0.000	1.021	0.021	0.004	0.004	1.016	0.016	0.008
IPX203-B16-02		3	2	6.890	0.001	0.001	1.028	0.027	0.003	0.003	1.051	0.050	0.009
IPX203-B16-02		3	2	2.217	0.000	0.000	1.028	0.027	0.003	0.003	1.047	0.047	0.005
IPX203-B16-02		3	2	7.091	0.000	0.000	1.025	0.025	0.003	0.003	1.030	0.029	0.006
IPX203-B16-02		3	2	3.061	0.001	0.001	1.025	0.024	0.002	0.002	1.041	0.040	0.007
IPX203-B16-02		3	5	0.090	0.000	0.000	1.015	0.015	0.000	0.000	0.985	0.015	0.000
IPX203-B16-02		1	2	15.839	0.002	0.002	0.994	0.006	0.003	0.003	0.969	0.031	0.015
IPX203-B16-02		3	2	13.997	0.001	0.001	1.020	0.020	0.002	0.002	1.022	0.022	0.007
IPX203-B16-02		3	5	1.384	0.000	0.000	1.019	0.019	0.001	0.001	1.013	0.013	0.003
IPX203-B16-02		1	2	34.310	0.004	0.004	0.982	0.018	0.028	0.029	0.950	0.051	0.057
IPX203-B16-02		3	2	75.611	0.007	0.006	1.008	0.009	0.073	0.073	1.040	0.042	0.118
IPX203-B16-02		2	2	1.317	0.000	0.000	1.021	0.021	0.001	0.001	1.030	0.029	0.003
IPX203-B16-02		3	2	5.530	0.001	0.001	1.026	0.025	0.002	0.002	1.035	0.035	0.007
IPX203-B16-02		3	2	7.792	0.003	0.003	1.027	0.027	0.011	0.011	1.008	0.009	0.029
IPX203-B16-02		3	2	57.226	0.003	0.003	0.996	0.004	0.017	0.017	0.983	0.017	0.034
IPX203-B16-02		3	5	0.625	0.000	0.000	1.021	0.021	0.001	0.001	1.016	0.016	0.002
IPX203-B16-02		2	2	1.914	0.000	0.000	1.015	0.015	0.001	0.001	1.025	0.024	0.004
IPX203-B16-02		2	2	60.175	0.003	0.003	0.976	0.025	0.034	0.035	0.936	0.065	0.057
IPX203-B16-02		3	2	15.787	0.002	0.002	1.033	0.033	0.010	0.009	1.061	0.060	0.022
IPX203-B16-02		3	2	14.275	0.005	0.005	0.997	0.003	0.055	0.057	0.982	0.017	0.091
IPX203-B16-02		3	2	7.531	0.001	0.001	1.028	0.028	0.004	0.004	1.053	0.052	0.010
IPX203-B16-02		3	2	2.717	0.000	0.000	1.025	0.025	0.003	0.003	1.036	0.036	0.004
IPX203-B16-02		3	2	2.833	0.001	0.001	1.023	0.023	0.002	0.002	1.034	0.034	0.006
IPX203-B16-02		3	2	1.584	0.000	0.000	1.025	0.025	0.002	0.002	1.040	0.039	0.005
IPX203-B16-02		1	2	0.285	0.000	0.000	1.009	0.008	0.001	0.001	1.016	0.016	0.001
IPX203-B16-02		3	2	12.964	0.004	0.004	1.009	0.009	0.030	0.030	1.005	0.005	0.057
IPX203-B16-02		3	2	3.912	0.001	0.001	1.020	0.020	0.003	0.003	1.028	0.028	0.010
IPX203-B16-02		3	2	30.728	0.003	0.003	1.001	0.001	0.019	0.019	0.993	0.007	0.039
IPX203-B16-02		3	2	16.137	0.005	0.005	0.989	0.011	0.067	0.069	0.970	0.030	0.106
IPX203-B16-02		3	2	4.305	0.001	0.001	1.031	0.031	0.002	0.002	1.038	0.037	0.008
IPX203-B16-02		3	2	5.914	0.001	0.001	1.031	0.030	0.003	0.003	1.042	0.041	0.008
IPX203-B16-02		3	2	23.710	0.002	0.002	1.021	0.020	0.009	0.009	1.033	0.033	0.020
IPX203-B16-02		3	5	1.382	0.000	0.000	1.013	0.013	0.000	0.000	0.989	0.011	0.000
IPX203-B16-02		3	2	95.259	0.017	0.018	0.898	0.104	0.803	0.904	0.801	0.212	0.993
IPX203-B16-02		3	2	2.840	0.001	0.001	1.020	0.020	0.002	0.002	1.030	0.030	0.009
IPX203-B16-02		3	2	11.047	0.001	0.001	1.025	0.024	0.003	0.003	1.036	0.036	0.009
IPX203-B16-02		3	2	12.830	0.001	0.001	1.024	0.024	0.003	0.003	1.037	0.037	0.009
IPX203-B16-02		3	2	7.592	0.001	0.001	1.023	0.023	0.003	0.003	1.034	0.033	0.011
IPX203-B16-02		3	2	13.622	0.001	0.001	1.018	0.018	0.003	0.003	1.028	0.028	0.007
IPX203-B16-02		3	2	77.930	0.004	0.004	0.986	0.014	0.061	0.062	0.979	0.020	0.087
IPX203-B16-02		3	2	10.912	0.001	0.001	1.017	0.017	0.004	0.004	1.014	0.014	0.014
IPX203-B16-02		3	2	1.168	0.000	0.000	1.030	0.030	0.003	0.003	1.059	0.058	0.005
IPX203-B16-02		3	2	1.741	0.001	0.001	1.032	0.031	0.003	0.003	1.053	0.052	0.006
IPX203-B16-02		1	2	1.680	0.000	0.000	1.006	0.006	0.001	0.001	1.009	0.009	0.002
IPX203-B16-02		3	2	11.617	0.001	0.001	1.020	0.020	0.004	0.004	1.012	0.012	0.008
IPX203-B16-02		3	2	8.798	0.002	0.002	1.023	0.023	0.011	0.011	1.052	0.052	0.025
IPX203-B16-02		3	2	21.583	0.001	0.001	1.018	0.018	0.003	0.003	1.029	0.028	0.011
IPX203-B16-02		3	2	6.437	0.001	0.001	1.024	0.023	0.004	0.004	1.038	0.037	0.012
IPX203-B16-02		3	2	13.254	0.002	0.002	1.032	0.032	0.004	0.004	1.047	0.046	0.015
IPX203-B16-02		2	2	1.494	0.000	0.000	1.024	0.024	0.001	0.001	1.028	0.027	0.004
IPX203-B16-02		1	2	0.349	0.000	0.000	1.009	0.009	0.001	0.001	1.016	0.016	0.001
IPX203-B16-02		3	2	57.930	0.005	0.005	1.007	0.007	0.016	0.016	1.008	0.008	0.051
IPX203-B16-02		3	2	63.419	0.004	0.004	1.018	0.018	0.059	0.058	1.065	0.066	0.086
IPX203-B16-02		3	5	1.391	0.000	0.000	1.021	0.020	0.001	0.001	1.014	0.014	0.003
IPX203-B16-02		3	2	53.572	0.012	0.013	0.939	0.062	0.364	0.393	0.870	0.135	0.472
IPX203-B16-02		3	2	14.930	0.001	0.001	1.022	0.022	0.004	0.004	1.036	0.036	0.013
IPX203-B16-02		1	2	0.022	0.000	0.000	1.010	0.010	0.001	0.001	1.019	0.019	0.001
IPX203-B16-02		3	2	32.504	0.006	0.006	0.989	0.011	0.070	0.073	0.973	0.026	0.112
IPX203-B16-02		3	2	15.404	0.002	0.002	1.020	0.020	0.007	0.007	1.033	0.032	0.020
IPX203-B16-02		3	2	14.359	0.001	0.001	1.024	0.023	0.003	0.003	1.039	0.038	0.012
IPX203-B16-02		3	2	7.293	0.001	0.001	1.034	0.034	0.005	0.005	1.067	0.066	0.011
IPX203-B16-02		3	2	18.387	0.001	0.001	1.022	0.021	0.003	0.003	1.039	0.039	0.011
IPX203-B16-02		3	2	24.602	0.005	0.005	0.993	0.007	0.046	0.047	0.969	0.032	0.080
IPX203-B16-02		3	2	53.505	0.003	0.003	1.000	0.000	0.018	0.019	0.993	0.007	0.039


IPX203-B16-02-	(b) (6)	3	2	13.283	0.002	0.002	1.037	0.036	0.008	0.008	1.070	0.069	0.021
IPX203-B16-02-		3	2	27.352	0.005	0.005	0.988	0.012	0.068	0.070	0.958	0.042	0.109
IPX203-B16-02-		3	2	4.742	0.002	0.002	1.019	0.019	0.004	0.004	1.030	0.030	0.015
IPX203-B16-02-		3	2	8.494	0.001	0.001	1.019	0.019	0.003	0.003	1.020	0.020	0.010
IPX203-B16-02-		3	2	1.138	0.000	0.000	1.034	0.034	0.003	0.003	1.054	0.053	0.006
IPX203-B16-02-		2	2	49.569	0.011	0.012	0.939	0.062	0.265	0.283	0.825	0.187	0.361
IPX203-B16-02-		3	2	5.816	0.001	0.001	1.029	0.029	0.006	0.006	1.067	0.066	0.013
IPX203-B16-02-		3	2	58.451	0.006	0.006	0.994	0.006	0.028	0.029	0.954	0.045	0.070
IPX203-B16-02-		2	2	2.120	0.000	0.000	1.017	0.017	0.002	0.002	1.025	0.025	0.003
IPX203-B16-02-		3	2	1.138	0.000	0.000	1.030	0.029	0.003	0.003	1.051	0.050	0.005
IPX203-B16-02-		3	2	4.956	0.001	0.001	1.024	0.024	0.005	0.005	1.047	0.046	0.014
IPX203-B16-02-		3	2	27.803	0.002	0.002	1.002	0.002	0.011	0.011	0.985	0.015	0.024
IPX203-B16-02-		3	2	96.582	0.007	0.007	0.976	0.024	0.048	0.049	0.926	0.075	0.095
IPX203-B16-02-		3	5	0.741	0.000	0.000	1.015	0.015	0.000	0.000	0.989	0.011	0.001
IPX203-B16-02-		3	2	48.817	0.003	0.003	0.993	0.007	0.022	0.023	0.966	0.033	0.044
IPX203-B16-02-		3	2	52.631	0.006	0.006	1.034	0.034	0.079	0.075	1.124	0.126	0.114
IPX203-B16-02-		2	2	11.258	0.001	0.001	1.010	0.010	0.002	0.002	1.001	0.001	0.009
IPX203-B16-02-		3	2	32.570	0.003	0.003	1.006	0.006	0.009	0.009	0.986	0.013	0.028
IPX203-B16-02-		3	2	55.221	0.011	0.011	0.987	0.013	0.130	0.136	0.936	0.065	0.221
IPX203-B16-02-		3	2	4.062	0.000	0.000	1.029	0.029	0.003	0.003	1.046	0.045	0.005
IPX203-B16-02-		3	2	55.094	0.004	0.004	1.000	0.000	0.039	0.040	1.004	0.004	0.068
IPX203-B16-02-		3	2	5.194	0.000	0.000	1.028	0.028	0.003	0.003	1.047	0.046	0.005
IPX203-B16-02-		3	2	14.245	0.001	0.001	1.023	0.023	0.004	0.004	1.035	0.034	0.013
IPX203-B16-02-		3	2	22.484	0.002	0.002	1.013	0.013	0.010	0.010	1.022	0.022	0.025
IPX203-B16-02-		3	5	0.660	0.000	0.000	1.016	0.016	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		1	2	0.061	0.000	0.000	1.010	0.010	0.001	0.001	1.018	0.018	0.001
IPX203-B16-02-		3	5	3.109	0.000	0.000	1.014	0.014	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		3	2	7.758	0.000	0.000	1.024	0.023	0.002	0.002	1.034	0.033	0.005
IPX203-B16-02-		3	2	38.361	0.003	0.003	1.014	0.014	0.021	0.021	1.035	0.035	0.042
IPX203-B16-02-		3	5	0.940	0.000	0.000	1.012	0.012	0.000	0.000	0.988	0.013	0.002
IPX203-B16-02-		3	2	5.203	0.001	0.001	1.023	0.023	0.002	0.002	1.026	0.026	0.010
IPX203-B16-02-		3	2	8.532	0.001	0.001	1.030	0.030	0.003	0.003	1.040	0.039	0.008
IPX203-B16-02-		3	5	0.445	0.000	0.000	1.013	0.013	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		3	2	5.573	0.001	0.001	1.022	0.022	0.003	0.003	1.035	0.034	0.009
IPX203-B16-02-		3	2	23.945	0.005	0.006	1.009	0.009	0.040	0.041	0.998	0.002	0.082
IPX203-B16-02-		3	5	1.672	0.000	0.000	1.013	0.013	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02-		2	2	1.846	0.001	0.001	1.019	0.019	0.001	0.001	1.025	0.025	0.005
IPX203-B16-02-		3	2	21.173	0.004	0.004	1.001	0.001	0.037	0.038	0.996	0.004	0.066
IPX203-B16-02-		3	5	1.338	0.000	0.000	1.015	0.015	0.000	0.000	0.989	0.012	0.002
IPX203-B16-02-		3	2	4.608	0.000	0.000	1.029	0.029	0.002	0.002	1.041	0.041	0.006
IPX203-B16-02-		3	2	22.543	0.002	0.002	1.021	0.021	0.006	0.006	1.031	0.030	0.019
IPX203-B16-02-		3	5	1.209	0.000	0.000	1.021	0.021	0.000	0.000	1.001	0.001	0.002
IPX203-B16-02-		3	5	0.088	0.000	0.000	1.012	0.012	0.000	0.000	0.985	0.016	0.000
IPX203-B16-02-		3	2	4.517	0.001	0.001	1.023	0.023	0.002	0.002	1.032	0.031	0.006
IPX203-B16-02-		3	2	23.006	0.002	0.002	1.024	0.024	0.003	0.003	1.022	0.022	0.020
IPX203-B16-02-		3	2	9.658	0.003	0.003	1.008	0.008	0.014	0.014	1.004	0.004	0.032
IPX203-B16-02-		3	5	0.907	0.000	0.000	1.014	0.014	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02-		3	2	12.794	0.001	0.001	1.022	0.022	0.002	0.002	1.028	0.028	0.009
IPX203-B16-02-		3	2	80.318	0.014	0.014	0.954	0.046	0.386	0.415	0.921	0.077	0.505
IPX203-B16-02-		3	2	21.069	0.000	0.000	1.015	0.015	0.005	0.005	1.029	0.029	0.007
IPX203-B16-02-		3	2	18.697	0.000	0.000	1.016	0.016	0.005	0.005	1.030	0.030	0.006
IPX203-B16-02-		3	2	11.725	0.002	0.002	1.022	0.022	0.017	0.016	1.032	0.032	0.028
IPX203-B16-02-		3	2	11.568	0.003	0.003	1.008	0.008	0.016	0.016	1.010	0.010	0.035
IPX203-B16-02-		3	2	36.968	0.001	0.001	1.006	0.006	0.008	0.008	1.015	0.016	0.012
IPX203-B16-02-		3	2	24.388	0.002	0.002	1.003	0.003	0.011	0.011	1.004	0.004	0.026
IPX203-B16-02-		3	2	25.123	0.002	0.002	0.998	0.002	0.018	0.019	0.996	0.004	0.037
IPX203-B16-02-		3	2	7.200	0.002	0.002	1.018	0.018	0.007	0.007	1.026	0.026	0.019
IPX203-B16-02-		3	2	14.387	0.001	0.001	1.013	0.013	0.004	0.004	1.023	0.023	0.013
IPX203-B16-02-		3	2	6.322	0.001	0.001	1.018	0.018	0.003	0.003	1.026	0.026	0.012
IPX203-B16-02-		3	2	7.616	0.001	0.001	1.020	0.020	0.002	0.002	1.034	0.033	0.007
IPX203-B16-02-		3	2	6.737	0.001	0.001	1.016	0.016	0.004	0.004	1.024	0.023	0.014
IPX203-B16-02-		3	2	11.423	0.000	0.000	1.022	0.022	0.004	0.004	1.036	0.036	0.005
IPX203-B16-02-		3	5	2.962	0.000	0.000	1.013	0.013	0.000	0.000	0.989	0.011	0.000
IPX203-B16-02-		3	2	2.754	0.001	0.001	1.027	0.027	0.006	0.006	1.044	0.043	0.012
IPX203-B16-02-		3	2	16.102	0.000	0.000	1.017	0.017	0.005	0.005	1.033	0.032	0.006
IPX203-B16-02-		3	5	3.881	0.000	0.000	1.013	0.013	0.000	0.000	0.992	0.008	0.000
IPX203-B16-02-		3	2	11.630	0.001	0.001	1.016	0.016	0.003	0.003	1.027	0.027	0.010
IPX203-B16-02-		3	2	20.732	0.001	0.001	1.014	0.014	0.005	0.005	1.027	0.027	0.009
IPX203-B16-02-		3	2	13.613	0.001	0.001	1.018	0.018	0.003	0.003	1.029	0.028	0.010
IPX203-B16-02-		3	2	5.236	0.000	0.000	1.024	0.023	0.003	0.003	1.038	0.038	0.005
IPX203-B16-02-		3	2	6.679	0.000	0.000	1.023	0.023	0.004	0.004	1.040	0.039	0.004
IPX203-B16-02-		3	2	0.050	0.000	0.000	1.030	0.030	0.004	0.004	1.049	0.048	0.005
IPX203-B16-02-		3	2	0.728	0.000	0.000	1.028	0.028	0.003	0.003	1.047	0.046	0.004
IPX203-B16-02-		3	2	9.800	0.001	0.001	1.018	0.018	0.003	0.003	1.031	0.031	0.008
IPX203-B16-02-		2	2	9.584	0.000	0.000	1.010	0.010	0.003	0.003	1.024	0.023	0.004
IPX203-B16-02-		3	2	7.966	0.000	0.000	1.022	0.022	0.004	0.004	1.038	0.038	0.004
IPX203-B16-02-		3	2	4.516	0.001	0.001	1.023	0.023	0.004	0.004	1.035	0.034	0.012
IPX203-B16-02-		3	2	2.649	0.001	0.001	1.027	0.026	0.005	0.004	1.042	0.041	0.009
IPX203-B16-02-		1	2	1.786	0.001	0.001	1.013	0.013	0.003	0.003	1.018	0.018	0.008
IPX203-B16-02-		3	2	23.851	0.001	0.001	1.013	0.013	0.005	0.005	1.022	0.022	0.011
IPX203-B16-02-		3	2	7.284	0.000	0.000	1.024	0.024	0.004	0.004	1.040	0.040	0.004
IPX203-B16-02-		3	2	21.548	0.001	0.001	1.008	0.009	0.006	0.006	1.015	0.015	0.016
IPX203-B16-02-		3	2	43.371	0.002	0.002	1.005	0.005	0.011	0.011	1.008	0.009	0.026
IPX203-B16-02-		3	2	12.125	0.001	0.001	1.016	0.016	0.003	0.003	1.030	0.030	0.008

IPX203-B16-02	(b) (6)	3	2	14.990	0.002	0.002	1.027	0.026	0.004	0.004	1.047	0.046	0.016
IPX203-B16-02		3	2	84.081	0.008	0.008	0.998	0.002	0.046	0.047	0.986	0.013	0.100
IPX203-B16-02		3	5	5.509	0.000	0.000	1.015	0.015	0.000	0.000	1.000	0.000	0.002
IPX203-B16-02		3	2	10.640	0.001	0.001	1.020	0.020	0.003	0.003	1.020	0.020	0.011
IPX203-B16-02		3	2	47.067	0.005	0.005	1.023	0.023	0.026	0.026	1.059	0.059	0.066
IPX203-B16-02		3	2	43.561	0.002	0.002	1.010	0.010	0.010	0.010	1.010	0.010	0.022
IPX203-B16-02		3	5	0.224	0.000	0.000	1.013	0.013	0.000	0.000	0.985	0.015	0.000
IPX203-B16-02		3	2	7.524	0.001	0.001	1.023	0.022	0.002	0.002	1.031	0.030	0.006
IPX203-B16-02		3	2	5.627	0.001	0.001	1.021	0.021	0.002	0.002	1.026	0.026	0.009
IPX203-B16-02		3	2	37.175	0.003	0.003	1.020	0.020	0.016	0.016	1.049	0.048	0.036
IPX203-B16-02		3	5	0.161	0.000	0.000	1.016	0.015	0.000	0.000	0.986	0.015	0.000
IPX203-B16-02		3	2	14.705	0.003	0.003	1.006	0.006	0.014	0.014	0.989	0.011	0.034
IPX203-B16-02		2	2	2.607	0.001	0.001	1.027	0.027	0.004	0.004	1.050	0.049	0.010
IPX203-B16-02		3	2	75.344	0.038	0.037	1.039	0.040	0.258	0.257	1.054	0.063	0.518
IPX203-B16-02		3	2	14.821	0.002	0.002	1.004	0.004	0.012	0.012	0.997	0.002	0.027
IPX203-B16-02		3	2	5.341	0.001	0.001	1.022	0.022	0.003	0.003	1.033	0.033	0.008
IPX203-B16-02		3	2	40.077	0.003	0.003	0.994	0.006	0.020	0.021	0.972	0.027	0.039
IPX203-B16-02		3	2	60.917	0.004	0.004	0.991	0.009	0.020	0.021	0.962	0.038	0.044
IPX203-B16-02		3	2	35.597	0.003	0.003	0.995	0.005	0.022	0.022	0.973	0.027	0.043
IPX203-B16-02		3	2	39.620	0.004	0.004	0.996	0.004	0.021	0.021	0.974	0.026	0.045
IPX203-B16-02		3	2	24.421	0.006	0.006	0.987	0.013	0.091	0.094	0.961	0.039	0.136
IPX203-B16-02		3	2	4.073	0.001	0.001	1.031	0.031	0.006	0.006	1.067	0.066	0.009
IPX203-B16-02		3	2	10.506	0.002	0.002	1.011	0.011	0.012	0.012	1.011	0.011	0.030
IPX203-B16-02		3	2	7.828	0.001	0.001	1.019	0.019	0.003	0.003	1.023	0.023	0.012
IPX203-B16-02		3	2	2.488	0.001	0.001	1.024	0.024	0.002	0.002	1.037	0.037	0.006
IPX203-B16-02		3	2	30.378	0.002	0.002	1.010	0.010	0.008	0.008	1.009	0.009	0.023
IPX203-B16-02		3	2	4.411	0.001	0.001	1.028	0.027	0.002	0.002	1.028	0.028	0.010
IPX203-B16-02		3	2	22.483	0.002	0.002	1.027	0.027	0.008	0.008	1.052	0.051	0.020
IPX203-B16-02		3	2	1.957	0.001	0.001	1.024	0.024	0.002	0.002	1.037	0.036	0.006
IPX203-B16-02		2	2	27.497	0.003	0.003	1.023	0.023	0.058	0.055	1.077	0.080	0.077
IPX203-B16-02		3	5	1.016	0.000	0.000	1.015	0.015	0.000	0.000	0.992	0.008	0.001
IPX203-B16-02		3	2	12.048	0.003	0.003	1.008	0.008	0.016	0.016	1.002	0.002	0.035
IPX203-B16-02		3	2	5.960	0.000	0.000	1.027	0.027	0.003	0.003	1.036	0.036	0.006
IPX203-B16-02		3	2	9.667	0.001	0.001	1.020	0.020	0.003	0.003	1.032	0.031	0.007
IPX203-B16-02		3	2	13.855	0.001	0.001	1.023	0.023	0.003	0.003	1.031	0.030	0.011
IPX203-B16-02		3	2	2.516	0.001	0.001	1.022	0.022	0.002	0.002	1.033	0.032	0.006
IPX203-B16-02		3	2	1.455	0.000	0.000	1.023	0.023	0.002	0.002	1.036	0.036	0.005
IPX203-B16-02		3	2	3.665	0.001	0.001	1.022	0.022	0.003	0.003	1.027	0.026	0.010
IPX203-B16-02		3	5	1.100	0.000	0.000	1.019	0.019	0.001	0.001	1.012	0.012	0.003
IPX203-B16-02		1	2	6.028	0.001	0.001	1.007	0.007	0.000	0.000	1.000	0.000	0.007
IPX203-B16-02		3	2	3.946	0.001	0.001	1.021	0.020	0.002	0.002	1.031	0.031	0.007
IPX203-B16-02		3	2	2.303	0.001	0.001	1.022	0.022	0.002	0.002	1.034	0.033	0.006
IPX203-B16-02		3	2	57.259	0.003	0.003	0.993	0.007	0.042	0.043	0.985	0.015	0.067
IPX203-B16-02		3	2	37.140	0.008	0.008	0.969	0.031	0.183	0.193	0.924	0.077	0.252
IPX203-B16-02		3	2	27.567	0.001	0.001	1.016	0.016	0.006	0.006	1.023	0.022	0.014
IPX203-B16-02		1	2	0.059	0.000	0.000	1.010	0.010	0.001	0.001	1.017	0.016	0.001
IPX203-B16-02		3	2	13.144	0.003	0.004	1.000	0.000	0.028	0.029	0.990	0.010	0.054
IPX203-B16-02		1	2	0.959	0.000	0.000	1.008	0.008	0.001	0.001	1.013	0.013	0.001
IPX203-B16-02		3	2	1.240	0.000	0.000	1.028	0.027	0.002	0.002	1.036	0.035	0.005
IPX203-B16-02		3	2	14.104	0.003	0.003	1.013	0.013	0.014	0.014	1.005	0.005	0.033
IPX203-B16-02		1	2	7.648	0.001	0.001	1.001	0.001	0.000	0.000	0.999	0.001	0.004
IPX203-B16-02		3	2	9.568	0.001	0.001	1.019	0.019	0.003	0.003	1.025	0.024	0.011
IPX203-B16-02		3	2	17.524	0.004	0.004	0.999	0.001	0.036	0.037	0.993	0.007	0.063
IPX203-B16-02		3	2	30.320	0.001	0.001	1.006	0.006	0.007	0.008	0.987	0.012	0.014
IPX203-B16-02		3	2	215.739	0.040	0.040	0.928	0.073	0.289	0.311	0.810	0.203	0.627
IPX203-B16-02		3	2	6.738	0.002	0.002	1.023	0.023	0.009	0.008	1.051	0.050	0.021
IPX203-B16-02		3	2	17.476	0.001	0.001	1.013	0.013	0.006	0.006	1.001	0.002	0.013
IPX203-B16-02		3	2	20.301	0.002	0.002	1.023	0.023	0.006	0.006	1.004	0.004	0.022
IPX203-B16-02		3	5	2.203	0.000	0.000	1.013	0.013	0.000	0.000	0.993	0.008	0.001
IPX203-B16-02		3	2	4.695	0.001	0.001	1.032	0.032	0.006	0.006	1.068	0.067	0.013
IPX203-B16-02		3	2	15.387	0.005	0.005	0.996	0.004	0.057	0.058	0.973	0.027	0.094
IPX203-B16-02		3	5	0.878	0.000	0.000	1.012	0.012	0.000	0.000	0.987	0.013	0.002
IPX203-B16-02		3	2	41.974	0.007	0.007	1.023	0.023	0.009	0.009	1.018	0.018	0.060
IPX203-B16-02		3	2	27.968	0.001	0.001	1.015	0.015	0.006	0.006	1.026	0.026	0.015
IPX203-B16-02		3	2	11.177	0.002	0.002	1.016	0.016	0.006	0.006	1.020	0.020	0.017
IPX203-B16-02		3	5	1.432	0.000	0.000	1.017	0.017	0.000	0.000	1.000	0.001	0.002
IPX203-B16-02		3	2	17.941	0.001	0.001	1.023	0.022	0.004	0.004	1.037	0.036	0.011
IPX203-B16-02		3	5	1.942	0.000	0.000	1.023	0.023	0.001	0.001	1.014	0.014	0.003
IPX203-B16-02		3	5	1.575	0.000	0.000	1.012	0.012	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02		3	2	9.745	0.001	0.001	1.022	0.022	0.003	0.003	1.032	0.031	0.009
IPX203-B16-02		1	2	3.892	0.001	0.001	1.009	0.009	0.000	0.000	1.008	0.008	0.005
IPX203-B16-02		3	2	2.753	0.001	0.001	1.023	0.023	0.002	0.002	1.038	0.038	0.007
IPX203-B16-02		2	2	7.553	0.001	0.001	1.016	0.016	0.002	0.002	1.029	0.029	0.007
IPX203-B16-02		3	2	9.039	0.001	0.001	1.020	0.020	0.003	0.003	1.027	0.026	0.008
IPX203-B16-02		2	2	40.848	0.003	0.003	0.995	0.005	0.016	0.016	0.983	0.017	0.036
IPX203-B16-02		3	2	10.107	0.002	0.002	1.019	0.019	0.011	0.011	1.040	0.040	0.027
IPX203-B16-02		1	2	6.298	0.002	0.002	1.015	0.015	0.002	0.002	1.023	0.023	0.014
IPX203-B16-02		3	2	6.001	0.001	0.001	1.033	0.032	0.003	0.003	1.054	0.053	0.010
IPX203-B16-02		3	2	30.499	0.003	0.003	1.004	0.004	0.023	0.024	0.995	0.005	0.048
IPX203-B16-02		1	2	10.893	0.002	0.002	1.004	0.004	0.001	0.001	0.997	0.003	0.018
IPX203-B16-02		3	5	0.789	0.000	0.000	1.017	0.017	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02		1	2	0.033	0.000	0.000	1.010	0.010	0.001	0.001	1.022	0.021	0.001
IPX203-B16-02		3	2	4.668	0.001	0.001	1.021	0.021	0.002	0.002	1.027	0.026	0.007
IPX203-B16-02		3	2	5.613	0.000	0.000	1.022	0.021	0.003	0.003	1.032	0.031	0.005

IPX203-B16-02	(b) (6)	1	2	1.276	0.000	0.000	1.007	0.007	0.001	0.001	1.013	0.013	0.002
IPX203-B16-02		3	2	42.977	0.013	0.013	0.935	0.066	0.396	0.430	0.854	0.152	0.511
IPX203-B16-02		2	2	11.748	0.002	0.002	1.022	0.022	0.009	0.009	1.046	0.046	0.018
IPX203-B16-02		1	2	3.130	0.001	0.001	1.013	0.013	0.003	0.003	1.030	0.030	0.007
IPX203-B16-02		3	2	78.717	0.004	0.004	0.981	0.019	0.032	0.033	0.950	0.050	0.059
IPX203-B16-02		3	2	9.143	0.001	0.001	1.025	0.025	0.005	0.005	1.048	0.047	0.014
IPX203-B16-02		3	2	16.883	0.002	0.002	1.013	0.013	0.007	0.007	1.003	0.003	0.022
IPX203-B16-02		3	2	19.215	0.007	0.007	0.979	0.021	0.110	0.115	0.946	0.054	0.162
IPX203-B16-02		3	2	0.644	0.000	0.000	1.032	0.031	0.003	0.003	1.056	0.055	0.005
IPX203-B16-02		3	5	0.123	0.000	0.000	1.020	0.020	0.000	0.000	0.995	0.005	0.001
IPX203-B16-02		1	2	41.234	0.005	0.005	0.964	0.036	0.042	0.043	0.891	0.113	0.075
IPX203-B16-02		3	2	10.544	0.002	0.002	1.032	0.032	0.005	0.005	1.052	0.051	0.015
IPX203-B16-02		2	2	19.966	0.002	0.002	1.016	0.016	0.011	0.011	1.031	0.031	0.025
IPX203-B16-02		2	2	45.477	0.005	0.005	1.003	0.004	0.050	0.050	1.009	0.011	0.081
IPX203-B16-02		3	2	127.532	0.016	0.016	0.949	0.052	0.282	0.302	0.893	0.110	0.419
IPX203-B16-02		3	3	189.801	0.034	0.036	0.852	0.152	1.998	2.409	0.727	0.294	2.543
IPX203-B16-02		3	2	18.386	0.001	0.001	1.026	0.026	0.008	0.007	1.053	0.052	0.015
IPX203-B16-02		3	2	14.920	0.004	0.004	1.003	0.003	0.032	0.033	0.988	0.012	0.060
IPX203-B16-02		3	5	1.818	0.000	0.000	1.016	0.016	0.000	0.000	1.002	0.002	0.002
IPX203-B16-02		3	2	21.843	0.001	0.001	1.015	0.015	0.004	0.004	1.017	0.017	0.011
IPX203-B16-02		2	2	25.934	0.005	0.005	0.983	0.017	0.057	0.059	0.950	0.050	0.093
IPX203-B16-02		3	2	7.567	0.002	0.002	1.016	0.016	0.006	0.006	1.016	0.016	0.020
IPX203-B16-02		3	2	21.864	0.002	0.002	1.013	0.013	0.012	0.012	1.018	0.018	0.027
IPX203-B16-02		3	2	70.720	0.004	0.004	1.000	0.000	0.057	0.058	1.014	0.015	0.089
IPX203-B16-02		3	2	30.804	0.002	0.002	1.017	0.017	0.015	0.015	1.030	0.030	0.031
IPX203-B16-02		3	2	5.779	0.001	0.001	1.023	0.023	0.003	0.003	1.028	0.028	0.011
IPX203-B16-02		3	2	3.333	0.001	0.001	1.023	0.023	0.002	0.002	1.033	0.033	0.008
IPX203-B16-02		3	2	10.703	0.003	0.003	1.010	0.010	0.013	0.013	1.009	0.010	0.031
IPX203-B16-02		3	2	2.149	0.000	0.000	1.024	0.024	0.002	0.002	1.039	0.039	0.006
IPX203-B16-02		3	2	7.649	0.001	0.001	1.025	0.025	0.003	0.003	1.042	0.041	0.006
IPX203-B16-02		3	2	4.981	0.001	0.001	1.025	0.025	0.002	0.002	1.039	0.038	0.006
IPX203-B16-02		3	2	14.152	0.001	0.001	1.022	0.022	0.003	0.003	1.030	0.030	0.013
IPX203-B16-02		3	2	6.173	0.001	0.001	1.022	0.022	0.005	0.005	1.044	0.044	0.015
IPX203-B16-02		3	2	19.755	0.002	0.002	1.016	0.016	0.005	0.005	1.000	0.000	0.018
IPX203-B16-02		3	2	8.775	0.003	0.003	1.012	0.012	0.013	0.013	1.018	0.019	0.031
IPX203-B16-02		3	5	1.895	0.000	0.000	1.012	0.012	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02		1	2	7.342	0.001	0.001	1.002	0.002	0.000	0.000	0.996	0.004	0.005
IPX203-B16-02		3	2	16.141	0.003	0.003	1.004	0.005	0.025	0.025	1.001	0.001	0.049
IPX203-B16-02		1	2	6.551	0.002	0.002	1.009	0.009	0.000	0.000	0.996	0.004	0.011
IPX203-B16-02		3	5	0.459	0.000	0.000	1.013	0.013	0.000	0.000	0.986	0.014	0.000
IPX203-B16-02		3	2	9.903	0.002	0.002	1.029	0.029	0.003	0.003	1.020	0.020	0.016
IPX203-B16-02		3	2	56.447	0.003	0.003	0.993	0.007	0.019	0.019	0.976	0.023	0.036
IPX203-B16-02		3	5	0.206	0.000	0.000	1.015	0.015	0.000	0.000	0.985	0.015	0.001
IPX203-B16-02		3	2	6.912	0.000	0.000	1.022	0.022	0.003	0.003	1.031	0.031	0.005
IPX203-B16-02		3	2	14.857	0.001	0.001	1.023	0.023	0.003	0.003	1.020	0.020	0.012
IPX203-B16-02		2	2	11.840	0.002	0.002	1.002	0.002	0.005	0.005	0.993	0.007	0.016
IPX203-B16-02		3	2	3.117	0.000	0.000	1.024	0.024	0.002	0.002	1.036	0.035	0.006
IPX203-B16-02		3	2	4.995	0.001	0.001	1.030	0.030	0.004	0.004	1.051	0.050	0.010
IPX203-B16-02		3	2	1.839	0.000	0.000	1.029	0.028	0.003	0.003	1.048	0.047	0.005
IPX203-B16-02		2	2	5.307	0.001	0.001	1.014	0.014	0.003	0.003	1.018	0.018	0.012
IPX203-B16-02		3	2	2.374	0.001	0.001	1.022	0.022	0.002	0.002	1.035	0.034	0.006
IPX203-B16-02		3	2	3.949	0.001	0.001	1.021	0.021	0.003	0.003	1.028	0.028	0.011
IPX203-B16-02		3	2	4.800	0.001	0.001	1.022	0.022	0.004	0.004	1.029	0.029	0.013
IPX203-B16-02		3	2	9.603	0.001	0.001	1.024	0.023	0.004	0.004	1.041	0.040	0.014
IPX203-B16-02		3	2	19.992	0.001	0.001	1.021	0.021	0.003	0.003	1.025	0.025	0.011
IPX203-B16-02		3	5	0.607	0.000	0.000	1.014	0.014	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	5	2.915	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.014	0.001
IPX203-B16-02		3	5	0.423	0.000	0.000	1.014	0.014	0.000	0.000	0.986	0.014	0.001
IPX203-B16-02		3	2	38.585	0.004	0.004	1.009	0.009	0.019	0.019	1.005	0.005	0.046
IPX203-B16-02		3	2	9.888	0.002	0.002	1.018	0.018	0.007	0.007	1.029	0.029	0.021
IPX203-B16-02		3	2	2.140	0.001	0.001	1.024	0.024	0.002	0.002	1.038	0.038	0.006
IPX203-B16-02		3	2	3.036	0.001	0.001	1.036	0.036	0.011	0.010	1.098	0.096	0.017
IPX203-B16-02		3	2	85.173	0.014	0.014	0.925	0.077	0.396	0.426	0.826	0.184	0.512
IPX203-B16-02		3	2	9.196	0.003	0.002	1.053	0.052	0.047	0.042	1.150	0.148	0.061
IPX203-B16-02		3	2	38.166	0.001	0.001	0.993	0.007	0.025	0.027	0.959	0.039	0.034
IPX203-B16-02		3	2	4.485	0.001	0.001	1.031	0.031	0.003	0.003	1.047	0.046	0.009
IPX203-B16-02		3	5	1.543	0.000	0.000	1.020	0.020	0.001	0.001	1.014	0.014	0.003
IPX203-B16-02		3	2	33.850	0.008	0.008	0.969	0.031	0.166	0.174	0.934	0.065	0.231
IPX203-B16-02		3	2	39.924	0.002	0.002	0.992	0.007	0.029	0.031	0.956	0.042	0.040
IPX203-B16-02		3	2	190.794	0.036	0.036	0.915	0.086	0.304	0.334	0.761	0.252	0.550
IPX203-B16-02		3	2	8.388	0.000	0.000	1.019	0.019	0.006	0.006	1.031	0.031	0.007
IPX203-B16-02		2	2	2.706	0.001	0.001	1.039	0.039	0.001	0.001	1.026	0.025	0.006
IPX203-B16-02		3	5	0.605	0.000	0.000	1.015	0.015	0.000	0.000	0.988	0.012	0.001
IPX203-B16-02		3	2	14.043	0.001	0.001	1.017	0.017	0.003	0.003	1.013	0.013	0.009
IPX203-B16-02		3	2	9.819	0.000	0.000	1.019	0.018	0.003	0.003	1.021	0.021	0.007
IPX203-B16-02		3	2	34.599	0.002	0.002	1.006	0.006	0.008	0.008	0.988	0.012	0.021
IPX203-B16-02		3	2	9.287	0.002	0.002	1.024	0.024	0.012	0.012	1.057	0.056	0.024
IPX203-B16-02		3	2	22.005	0.001	0.001	1.011	0.011	0.005	0.005	1.002	0.002	0.011
IPX203-B16-02		3	2	4.117	0.001	0.001	1.022	0.022	0.003	0.003	1.038	0.037	0.010
IPX203-B16-02		3	2	2.651	0.000	0.000	1.027	0.027	0.003	0.003	1.036	0.036	0.005
IPX203-B16-02		3	2	5.658	0.001	0.001	1.024	0.023	0.003	0.003	1.038	0.038	0.008
IPX203-B16-02		3	2	22.850	0.001	0.001	1.021	0.021	0.005	0.004	1.033	0.033	0.013
IPX203-B16-02		3	2	26.211	0.008	0.008	0.974	0.026	0.154	0.162	0.944	0.056	0.216
IPX203-B16-02		3	2	26.279	0.005	0.005	1.032	0.032	0.005	0.005	1.034	0.033	0.040


IPX203-B16-02	(b) (6)	3	5	1.352	0.000	0.000	1.013	0.013	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02		3	2	17.611	0.004	0.004	1.003	0.003	0.033	0.033	0.995	0.005	0.062
IPX203-B16-02		3	2	2.098	0.000	0.000	1.033	0.033	0.002	0.002	1.037	0.036	0.006
IPX203-B16-02		3	2	48.251	0.006	0.006	1.004	0.004	0.031	0.031	0.991	0.009	0.072
IPX203-B16-02		3	2	20.068	0.002	0.002	1.028	0.028	0.005	0.005	1.037	0.036	0.020
IPX203-B16-02		3	2	31.377	0.004	0.004	0.998	0.002	0.041	0.042	0.994	0.006	0.071
IPX203-B16-02		3	2	14.076	0.002	0.002	1.015	0.015	0.009	0.009	1.022	0.021	0.024
IPX203-B16-02		3	2	11.872	0.001	0.001	1.030	0.030	0.003	0.003	1.039	0.039	0.012
IPX203-B16-02		3	2	3.033	0.001	0.001	1.021	0.021	0.002	0.002	1.030	0.029	0.008
IPX203-B16-02		3	2	8.970	0.002	0.002	1.013	0.013	0.008	0.008	1.010	0.010	0.023
IPX203-B16-02		3	2	2.176	0.001	0.001	1.023	0.023	0.002	0.002	1.035	0.035	0.007
IPX203-B16-02		3	2	21.842	0.006	0.006	0.994	0.006	0.074	0.076	0.969	0.031	0.120
IPX203-B16-02		3	2	15.289	0.004	0.004	1.000	0.000	0.037	0.038	0.990	0.010	0.066
IPX203-B16-02		3	2	6.063	0.002	0.002	1.017	0.017	0.006	0.006	1.020	0.020	0.020
IPX203-B16-02		3	2	8.293	0.002	0.002	1.019	0.019	0.005	0.005	1.025	0.025	0.017
IPX203-B16-02		3	2	57.745	0.012	0.012	1.020	0.020	0.030	0.031	1.019	0.020	0.118
IPX203-B16-02		3	2	11.398	0.001	0.001	1.022	0.022	0.003	0.003	1.036	0.035	0.010
IPX203-B16-02		2	2	9.373	0.004	0.004	1.034	0.034	0.002	0.002	1.011	0.011	0.028
IPX203-B16-02		3	2	7.542	0.001	0.001	1.034	0.034	0.003	0.003	1.044	0.043	0.011
IPX203-B16-02		3	2	9.782	0.002	0.002	1.010	0.010	0.011	0.011	1.008	0.008	0.027
IPX203-B16-02		3	2	10.512	0.002	0.002	1.011	0.011	0.011	0.011	1.007	0.007	0.028
IPX203-B16-02		3	2	5.324	0.001	0.001	1.017	0.017	0.004	0.004	1.021	0.021	0.014
IPX203-B16-02		3	2	12.135	0.001	0.001	1.019	0.019	0.002	0.002	1.027	0.026	0.008
IPX203-B16-02		3	2	13.259	0.002	0.002	1.008	0.008	0.012	0.013	1.005	0.005	0.030
IPX203-B16-02		3	5	0.592	0.000	0.000	1.012	0.012	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	5.656	0.001	0.001	1.020	0.020	0.002	0.002	1.028	0.028	0.008
IPX203-B16-02		3	2	3.949	0.001	0.001	1.017	0.016	0.004	0.004	1.021	0.020	0.014
IPX203-B16-02		3	2	3.082	0.001	0.001	1.022	0.021	0.002	0.002	1.030	0.030	0.007
IPX203-B16-02		3	5	1.226	0.000	0.000	1.013	0.013	0.000	0.000	0.988	0.013	0.001
IPX203-B16-02		3	5	0.174	0.000	0.000	1.012	0.012	0.000	0.000	0.986	0.015	0.000
IPX203-B16-02		3	2	11.471	0.001	0.001	1.022	0.022	0.002	0.002	1.033	0.032	0.009
IPX203-B16-02		3	2	1.244	0.000	0.000	1.025	0.024	0.003	0.002	1.039	0.039	0.005
IPX203-B16-02		3	5	0.702	0.000	0.000	1.012	0.012	0.000	0.000	0.988	0.012	0.002
IPX203-B16-02		3	2	13.239	0.002	0.002	1.030	0.030	0.003	0.003	1.038	0.038	0.013
IPX203-B16-02		3	2	10.980	0.002	0.002	1.011	0.011	0.007	0.007	1.016	0.016	0.019
IPX203-B16-02		3	2	34.264	0.006	0.006	1.029	0.029	0.052	0.051	1.050	0.051	0.092
IPX203-B16-02		3	2	7.160	0.000	0.000	1.022	0.021	0.003	0.003	1.035	0.034	0.005
IPX203-B16-02		3	2	51.862	0.004	0.004	0.986	0.014	0.044	0.045	0.964	0.036	0.077
IPX203-B16-02		3	2	101.982	0.013	0.013	0.967	0.033	0.108	0.112	0.929	0.072	0.194
IPX203-B16-02		3	2	45.485	0.001	0.001	1.000	0.000	0.011	0.012	0.995	0.005	0.019
IPX203-B16-02		3	5	1.182	0.000	0.000	1.012	0.011	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	18.524	0.000	0.000	1.014	0.014	0.005	0.005	1.020	0.020	0.008
IPX203-B16-02		3	2	22.904	0.001	0.001	1.015	0.015	0.006	0.006	1.016	0.016	0.012
IPX203-B16-02		3	2	38.353	0.001	0.001	1.000	0.000	0.010	0.010	0.995	0.004	0.020
IPX203-B16-02		3	2	28.586	0.001	0.001	1.004	0.004	0.008	0.008	1.002	0.002	0.019
IPX203-B16-02		3	2	9.403	0.002	0.002	1.034	0.034	0.011	0.011	1.055	0.054	0.023
IPX203-B16-02		3	2	5.313	0.000	0.000	1.024	0.024	0.004	0.004	1.039	0.038	0.004
IPX203-B16-02		3	5	2.277	0.000	0.000	1.015	0.015	0.000	0.000	1.004	0.004	0.002
IPX203-B16-02		3	2	1.859	0.000	0.000	1.025	0.025	0.002	0.002	1.043	0.043	0.005
IPX203-B16-02		3	2	11.433	0.003	0.003	1.008	0.008	0.016	0.016	1.008	0.009	0.035
IPX203-B16-02		3	2	4.514	0.000	0.000	1.033	0.032	0.008	0.008	1.061	0.060	0.011
IPX203-B16-02		3	2	3.832	0.001	0.001	1.026	0.026	0.004	0.004	1.043	0.043	0.011
IPX203-B16-02		3	2	4.323	0.001	0.001	1.020	0.019	0.004	0.004	1.034	0.033	0.012
IPX203-B16-02		3	2	30.997	0.001	0.001	1.007	0.007	0.007	0.008	1.008	0.008	0.012
IPX203-B16-02		3	2	31.031	0.002	0.002	1.015	0.016	0.008	0.008	1.011	0.011	0.024
IPX203-B16-02		3	2	43.033	0.006	0.006	0.989	0.010	0.137	0.141	0.973	0.025	0.186
IPX203-B16-02		3	2	9.076	0.001	0.001	1.022	0.022	0.003	0.003	1.020	0.020	0.012
IPX203-B16-02		3	2	17.584	0.003	0.003	1.009	0.009	0.012	0.012	1.000	0.000	0.030
IPX203-B16-02		3	5	1.577	0.000	0.000	1.022	0.021	0.001	0.001	1.014	0.014	0.003
IPX203-B16-02		3	2	33.038	0.002	0.002	1.008	0.008	0.009	0.009	0.998	0.002	0.024
IPX203-B16-02		3	2	13.987	0.003	0.003	1.021	0.021	0.013	0.013	1.031	0.031	0.033
IPX203-B16-02		3	2	13.116	0.000	0.000	1.019	0.019	0.003	0.003	1.022	0.022	0.006
IPX203-B16-02		3	2	1.967	0.000	0.000	1.026	0.026	0.002	0.002	1.041	0.040	0.006
IPX203-B16-02		3	5	0.546	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	12.479	0.001	0.001	1.024	0.024	0.008	0.008	1.053	0.053	0.016
IPX203-B16-02		3	2	5.799	0.002	0.002	1.014	0.014	0.007	0.008	1.015	0.015	0.022
IPX203-B16-02		1	2	0.109	0.000	0.000	1.010	0.010	0.001	0.001	1.019	0.019	0.001
IPX203-B16-02		3	2	14.915	0.001	0.001	1.018	0.018	0.003	0.003	1.030	0.029	0.012
IPX203-B16-02		3	2	12.154	0.003	0.003	1.007	0.007	0.019	0.019	1.001	0.001	0.040
IPX203-B16-02		3	2	25.149	0.002	0.002	1.020	0.020	0.006	0.006	1.035	0.034	0.019
IPX203-B16-02		3	2	8.782	0.001	0.001	1.020	0.020	0.004	0.004	1.029	0.029	0.013
IPX203-B16-02		3	2	13.193	0.001	0.001	1.026	0.026	0.003	0.003	1.027	0.026	0.011
IPX203-B16-02		3	2	14.236	0.001	0.001	1.017	0.017	0.003	0.003	1.019	0.019	0.011
IPX203-B16-02		3	2	43.836	0.007	0.007	1.022	0.022	0.017	0.017	1.022	0.022	0.065
IPX203-B16-02		3	5	1.265	0.000	0.000	1.012	0.012	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	5	0.571	0.000	0.000	1.013	0.013	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	31.657	0.010	0.011	0.950	0.050	0.300	0.322	0.887	0.116	0.394
IPX203-B16-02		3	2	11.680	0.002	0.002	1.017	0.017	0.006	0.006	1.022	0.022	0.018
IPX203-B16-02		3	2	29.411	0.002	0.002	1.016	0.015	0.006	0.006	1.016	0.016	0.020
IPX203-B16-02		3	5	0.334	0.000	0.000	1.018	0.017	0.000	0.000	0.987	0.013	0.001
IPX203-B16-02		3	2	27.639	0.006	0.006	1.000	0.000	0.050	0.051	0.981	0.019	0.090
IPX203-B16-02		3	2	24.367	0.007	0.007	0.981	0.019	0.107	0.111	0.951	0.049	0.157
IPX203-B16-02		3	2	11.765	0.001	0.001	1.020	0.020	0.004	0.003	1.025	0.025	0.009
IPX203-B16-02		3	2	4.856	0.001	0.001	1.027	0.027	0.003	0.003	1.033	0.032	0.007

IPX203-B16-02-	(b) (6)	3	2	27.323	0.009	0.009	0.963	0.037	0.217	0.230	0.907	0.095	0.293
IPX203-B16-02-		1	2	11.433	0.001	0.001	1.002	0.002	0.004	0.004	0.998	0.002	0.013
IPX203-B16-02-		3	2	18.368	0.004	0.004	1.002	0.002	0.029	0.029	0.991	0.009	0.054
IPX203-B16-02-		3	2	55.880	0.006	0.006	0.975	0.025	0.116	0.120	0.943	0.057	0.163
IPX203-B16-02-		3	2	23.804	0.002	0.002	1.020	0.020	0.006	0.006	1.031	0.030	0.017



***Note:** Four highlighted individuals showed the high influence on the fitted model, hence, the change from baseline to Visit7/ET in “Good on” Time during the double-blind treatment period

were displayed below. The same MMRM analyses were performed after excluding each high influential individual at a time to check these individuals leaning any change in the overall result.



IPX203 vs. IR CD-LD		
USUBJID EXCLUDED in the model	LS Mean Difference (95% CI)	p-value
IPX203-B16-02- (b) (6)	-0.5021 (-0.9205, -0.0837)	0.0187
IPX203-B16-02- (b) (6)	-0.5096 (-0.9258, -0.0934)	0.0164
IPX203-B16-02- (b) (6)	-0.4553 (-0.8746, -0.0361)	0.0333
IPX203-B16-02- (b) (6)	-0.5239 (-0.9366, -0.1113)	0.0129
IPX203-B16-02- (b) (6)	-0.4891 (-0.9101, -0.0681)	0.0228
IPX203-B16-02- (b) (6)	-0.4795 (-0.9003, -0.0586)	0.0256
IPX203-B16-02- (b) (6)	-0.4915 (-0.9116, -0.0714)	0.0219

7 Appendix II : Additional Efficacy Analyses by Requests

The reviewer received the request for additional efficacy analyses in the population after excluding 5 subjects who received the average daily dose of levodopa > 2400. Results from additional efficacy analyses demonstrated that the impact of 5 subjects who received overdose of daily average levodopa (> 2400) did not change the conclusion for the primary analysis.

Table 18 Summary of Study Drug Exposure in the Double-Blind Period (Randomized Analysis Set)

Characteristic Statistic	IPX203 (N=256)	IR CD-LD (N=250)
Average Daily Dose of Levodopa (mg)		
n	256	250
Mean (SD)	1488.05 (592.782)	856.94 (378.683)
Median (Min, Max)	1400.00 (420.0, 3360.0)	800.00 (400.0, 2100.0)
<400	0	0
400 - <800	29 (11.3)	115 (46.0)
800 - <1200	50 (19.5)	91 (36.4)
1200 - <1600	57 (22.3)	24 (9.6)
1600 - 2400	115 (44.9)	20 (8.0)
>2400	5 (2.0)	0

Source: Sponsor; Clinical Study Report page 105

Primary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Good on” Time during DBP by Randomized Treatment Group (mITT Analysis Set) – After excluding 5 subjects who received an average daily dose of LD >2400

Statistics (hour)	Randomized Treatment Group	
	IPX203 (N=249)	IR CD-LD (N=246)
LS Mean change (SE) at Week 12 from baseline	-0.4767 (0.1844)	-1.0291 (0.1824)
LS Mean difference (95% CI) (IPX203 vs. IR CD-LD)	0.5524 (0.1061, 0.9988)	
p-value	0.0154	

Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, Max=maximum, Min=minimum, Q1=quarter 1, Q3=quarter 3, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; adpddep.xpt, adsl.xpt

Key Secondary Efficacy Endpoint: Change from Baseline to Visit7/ET in “Off” Time during DBP by Randomized Treatment Group (mITT Analysis Set) – After excluding 5 subjects who received an average daily dose of LD >2400

Statistics (hour)	Randomized Treatment Group	
	IPX203 (N=249)	IR CD-LD (N=246)
LS Mean change (SE) at Week 12 from baseline	0.3582 (0.1739)	0.8598 (0.1721)
LS Mean difference (95% CI) (IPX203 vs. IR CD-LD)	-0.5016 (-0.9254, -0.0778)	
p-value	0.0205	

Abbreviations: DBP=double-blind treatment period, ET=early termination, mITT=modified intent-to-treat, IR CD-LD=immediate-release carbidopa-levodopa, N=number, SD=standard deviation, Max=maximum, Min=minimum, Q1=quarter 1, Q3=quarter 3, SE=standard error, CI=confidence interval.

The LS mean, SE, LS Mean Difference, 95% CIs and p-values have been obtained from the MMRM with treatment, visit as fixed effects, pooled center as a random effect, baseline assessment as a continuous fixed covariate, and a treatment-by-visit interaction.

Source: Statistical Reviewer Analysis; *adpdep.xpt*, *adsl.xpt*

Key Secondary Efficacy Endpoint: PGI-C Scores by Randomized Treatment Group (ITT Analysis Set) – After excluding 5 subjects who received an average daily dose of LD >2400

PGI-C Score	IPX203 (N=256) n (%)	IR CD-LD (N=250) n (%)
Much or very much improved	76 (29.7)	47 (18.8)
Percent difference (95% CI)	10.9 (3.5, 18.3)	
p-value*	0.0015	

Abbreviations: PGI-C=patient global impression of change, ITT= intent-to-treat, IR CD-LD=immediate carbidopa-levodopa, n=number.

* p-value from Cochran-Mantel-Haenszel test stratified by pooled center comparing the proportion of much or very much improved subjects between the treatment groups.

Note: For subjects with missing PGI-C, the data will be imputed as non-responders (i.e., not being “much improved” or “very much improved”).

Source: Statistical Reviewer Analysis; *adqseff.xpt*, *adsl.xpt*

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MINJEONG PARK
04/28/2023 12:32:14 PM

JOHN P LAWRENCE
04/28/2023 12:33:42 PM

HSIEN MING J HUNG
04/28/2023 12:42:08 PM